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Abstract: This review presents the biological activity—antibacterial, antifungal, anti-parasitic, 
antiviral, antitumor, antiinflammatory, antioxidant, and enzymatic activity—of halogenated 
marine natural products discovered in the past five years. Newly discovered examples that 
do not report biological activity are not included. 
Keywords: organohalogen; antibacterial; antiparasitic; antiviral; antitumor; antiinflammatory; 
antioxidant; natural products; organochlorine; organobromine 
 
1. Introduction 
From fewer than 50 examples of halogenated natural products that were known in 1968 [1], the 
number today is more than 5000 and steadily increasing [2–6]. A majority of these compounds are 
found in marine organisms and several recent reviews are available of marine natural products in  
general [7–10], in algae [11–13], in sponges [14–16], in invertebrates [17–19], in gorgonians [20],  
in bryophytes [21], in fungi [22], in cyanobacteria [23], in marine bacteria [24], and those  
cyano-containing marine triterpenoids [25]. Given the enormous advance in ocean exploration, 
including retrieving samples at depths reaching 11,000 m [26], it is inevitable that novel marine natural 
products are awaiting discovery. 
In the present review I have chosen to focus on halogenated marine natural products possessing 
demonstrated biological activity that were reported during the period 2011–2015. My organization is 
according to the type of observed activity, and many of these marine metabolites have multiple 
activities and therefore appear in more than one section. 
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2. Antibacterial Activity 
Natural products represent an important potential source of new antibacterial drugs [27], 
particularly those that prevent biofouling by barnacles, tubeworms, mussels, and other “smothering” 
marine organisms [28,29]. 
Many gorgonian soft coral metabolites are biofilm inhibitors. For example, the South China Sea 
gorgonian Dichotella gemmacea has yielded several antibacterial briarane diterpenoids 1–12, several 
of which contain chlorine, as summarized in Figure 1 [30,31]. 
 
Figure 1. Cont. 
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Figure 1. Structures of gemmacolide briarane diterpenoids from Dichotella gemmacea [30,31]. 
Of these gemmacolides, N (1), O (2), and Q (4) show antibacterial activity against the Gram-negative 
bacterium E. coli in the agar diffusion assay, with the chlorinated gemmacolide O being the most  
active [30]. Antitumor and antifungal activities are discussed in the appropriate sections to follow. 
The prolific gorgonian Dichotella gemmacea is also the source of numerous new briarane diterpenoids, 
the dichotellides, many of which contain chlorine or iodine or both [32–34]. In particular, of the 16 
novel briarane diterpenoids, dichotellides F–U, found in Dichotella gemmacea, H (13), I (14), K (15), 
L (16), M (17), N (18), O (19), P (20), and U (21) exhibit potent antifouling activities (Figure 2;  
Table 1) [34]. 
 
Figure 2. Structures of selected dichotellide briarane diterpenoids from Dichotella 
gemmacea [34]. 
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Table 1. Biofouling activity of dichotellides (13–21) against the larval settlement of the 
barnacle Balanus amphitrite [34]. 
Compound EC50 (μg/mL) a LC50/EC50 b 
H (13) 4.1 >24 
I (14) 1.82 >54.9 
K (15) 6.3 >16 
L (16) 7.6 >13 
M (17) 4.6 >11 
N (18) 1.2 >88 
O (19) 5.6 >18 
P (20) 0.79 >126.6 
U (21) 2.0 >48 
a Effective concentration for 50% inhibition; b Lethal concentration/effective concentration. 
The South China Sea gorgonian Junceella fragilis has also yielded 12 new briarane diterpenoids, 
fragilisinins A–L (22–33) (Figure 3), several of which have potent antifouling activity, but are not superior 
to the previously known junceelloide A and junceellonoid D (Table 2) [35]. 
 
 
Figure 3. Cont. 
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Figure 3. Structures of fragilisinins A–L briarane diterpenoids from Junceella fragilis [35]. 
Table 2. Biofouling activity of fragilisinins against the larval settlement of the barnacle 
Balanus amphitrite [35]. 
Compound EC50 (μM) LC50/EC50 
fragilisinin E (30) 14.0 >13 
fragilisinin F (32) 12.6 >14.5 
fragilisinin J (25) 11.9 >11.5 
junceellolide A (34) 5.6 >33.3 
junceellonoid D (35) 10.0 >20 
positive control a 2.5 – 
a 5-octylfuran-2(5H)-one. 
An examination of the Chinese soft coral Sinularia rigida has yielded 19 new cembrane 
diterpenoids, the sinulariols, of which J (36) and P (37) display antifouling activity against B. 
amphitrite (5.65 μg/mL) and B. neritina (14.03 µg/mL), respectively (Figure 4). The one chlorine-
containing example, sinulariol E (38) is less active [36]. 
 
Figure 4. Structures of selected sinulariol cembrane diterpenoids from Sinularia rigida [36]. 
Potent antifouling activity is observed in some newly isolated resorcylic acid lactones found in the 
fungus Cochlionbolus lunatus derived from the gorgonian Dichotella gemmacea. Thus obtained were 
cochliomycins A–C (39–41) (Figure 5) [37,38]. Only cochliomycin A (39) shows potent activity 
against Balanus amphitrite (EC50 1.2 μg/mL; LC50/EC50 > 16.7), which was superior to the known 
analogues zeaenol, LL-Z1640-1, and LL-Z1640-2. Insufficient material of cochliomycins B and C was 
available for testing. 
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Figure 5. Structures of cochliomycins A–C (39–41) from Cochliobolus lunatus [37,38]. 
Another soft-coral derived fungus, Pestalotiopsis sp. from the South China Sea Sarcophyton sp., 
contains the novel (±)-pestalachloride D (42) and the known analogue (±)-pestalachloride C (43)  
(Figure 6) [39,40]. Both compounds are active against the bacteria E. coli, Vibrio anguillarum, and 
Vibrio parahaemolyticus with MIC values of 5.0, 10.0, and 20.0 µM, respectively [39]. 
 
Figure 6. Structures of (±)-pestalachlorides D (42) and C (43) from Pestalotiopsis sp. [39,40]. 
The Antarctic soft coral Alcyonium roseum has yielded the two new illudalanes, alcyopterosins 44 
and 45 (Figure 7) [41]. Although insufficient material was available for antibacterial testing, the 
authors believe that these metabolites may be feeding deterrents for the predatory sea star Odontaster 
validus and have antifouling activity, based on similar properties of related alcyopterosins. The  
soft-coral associated actinomycetes strain, Streptomyces sp. OUCMDZ-1703 has yielded the novel 
strepchloritides A (46) and B (47), which exhibit modest activity against E. coli, Pseudomonas 
aeruginosa, and S. aureus (Figure 7). 
 
Figure 7. Structures of alcyopterosins 44 and 45 from Alcyonium roseum [41], and 
strepchloritides A (46) and B (47) from Streptomyces sp. OUCMDZ-1703 [42]. 
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The Mediterranean gorgonian Paramuricea clavata is reported to contain three new  
brominated metabolites, 2-bromo-N-methyltryptamine (48), 3-bromo-N-methyltyramine (49), and  
6-bromo-N-methyltryptamine (50) (Figure 8) in addition to several known analogues [43]. Compound 
50 was previously known from synthesis. Of the ten compounds tested, 48 shows the highest activity 
in preventing adhesion of three bacterial strains (Pseudoalteromonas sp. D41 and TC8, and Paracoccus sp. 
4M6). However, insufficient material was available for toxicity screening. 
The marine sponge Pseudoceratina sp. has yielded numerous brominated alkaloids with biological 
activity [2–4], including the four new pseudoceramines A–D (51–54) collected from this sponge in the 
Great Barrier Reef, Queensland, Australia (Figure 9) [44]. Pseudoceramine B (52) inhibits bacterial 
growth with IC50 40 µM. 
 
Figure 8. Brominated compounds 48–50 from Paramuricea clavata [43]. 
 
Figure 9. Structures of pseudoceramines A–D (51–54) from the sponge Pseudoceratina sp. [44]. 
Of the 12 bromotyrosines isolated from the southern Australian sponge Pseudoceratina sp., four  
were new metabolites: aplysamine-7 (55), (–)-purealin B (56), purealin C (57), and purealin D (58)  
(Figure 10) [45]. Purealin C shows a broad spectrum of activity against two strains each of the  
Mar. Drugs 2015, 13 4051 
 
 
Gram-positive S. aureus (IC50 2.6 and 6.2 µM) and B. subtilis (IC50 2.6 and 2.8 µM), while  
(–)-purealin B is only active against B. subtilis (IC50 3.4 and 3.8 µM). 
 
Figure 10. Structures of bromotyrosines 55–58 from the sponge Pseudoceratina sp. [45]. 
A collection of the sponge Iotrochota purpurea from Hainan Island, China, has yielded the ten new 
halogenated purpuroines A–J (59–68), five of which contain iodine (Figure 11) [46]. In addition to 
antifungal activity to be discussed in the next section, purpuroine I (67) shows selective inhibition  
of the human pathogen Streptococcus pneumonia (IC50 18.06 ± 0.76 µg/mL; ampicillin, IC50  
0.38 ± 0.029 µg/mL). 
 
Figure 11. Structures of purpuroines A–J (59–68) from the sponge Iotrochota purpurea [46]. 
The deep-sea Great Australian Bight sponge, Axinella sp., contains the three new brominated 
imidazoles, 14-O-sulfate massadine (69), 14-O-methyl massadine (70), and 3-O-methyl massadine 
chloride (71) (Figure 12) [47]. The latter chlorine-containing metabolite (71) exhibits antibacterial 
activity against the Gram-positive bacteria Staphylococcus aureus (ATCC 9144 and 25923; IC50 3.7 
and 4.2 µM, respectively) and B. subtilis (ATCC 6051 and 6633; IC50 2.6 and 2.2 µM, respectively), 
and the Gram-negative bacteria E. coli (ATCC 11775; IC50 4.4 µM) and P. aeruginosa (ATCC 10145; 
IC50 4.9 µM). The effect of the chlorine atom is noteworthy. 
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Figure 12. Structures of massadines 69–71 from the sponge Axinella sp. [47]. 
A deep-water Asteropus sponge from the Bahamas contains the novel indolo[3,2-a]carbazoles 72 
and 73 (Figure 13); 72 shows some activity against methicillin-resistant S. aureus (MRSA; minimum 
inhibitory concentration (MIC) of 50 µg/mL [48]. 
 
Figure 13. Structures of indolo[3,2-a]carbazoles 72 and 73 from the sponge Asteropus sp. [48]. 
Examination of the southern Australian sponge Ianthella sp. has revealed the presence of dictyodendrins 
F–J (74–78) (Figure 14) [49]. Antibacterial activity is limited to the Gram-positive B. subtilis (ATCC 
6051 and 6633): 74 (IC50 2.7 and 2.3 µM), 76 (IC50 1.2 and 3.1 µM), and 77 (IC50 2.5 and 2.8 µM). 
 
Figure 14. Structures of dictyodendrins F–J (74–78) from the sponge Ianthella sp. [49]. 
A series of structurally novel indole alkaloids was isolated from the Okinawan sponge Suberites sp., 
including nakijinamines A (79), B (80), F (81), G (82), H (83), I (84), and 6-bromoconicamin (85) 
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(Figure 15) [50]. An earlier study by this same research team identified the related nakijinamines C–E 
(not shown) [51]. Of these alkaloids, only nakijinamine A (79) is active against S. aureus (MIC  
16 µg/mL), B. subtilis (MIC 16 µg/mL), and Micrococcus luteus (MIC 2 µg/mL). Nakijinamine I (84) 
is the first aaptamine-type alkaloid to have a 1,4-dioxane unit. 
 
Figure 15. Structures of nakijinamines 79–84 and 6-bromoconicamin (85) from the sponge 
Suberites sp. [50]. 
The Okinawan sponge Agelas sp. is a rich source of brominated pyrrole alkaloids and several recent 
studies have added to this collection. The agelasines O–U (86–92) from Agelas sp. (NSS-19) are novel 
diterpene alkaloids tethered to a 9-N-methyladenine unit (Figure 16) [52]. Of these alkaloids, only 
agelasines O–R (86–89) and T (91) show activity against S. aureus and B. subtilis (MIC 8.0–32.0 µg/mL), 
but not against E. coli (MIC ≥ 32.0 µg/mL). For both strains the activity decreases: Q (88) ~ R (89)  
> O (86) ~ T (91) > P (87). 
 
Figure 16. Cont. 
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Figure 16. Structures of agelasines O–U (86–92) from the sponge Agelas sp. [52]. 
Another examination of the sponge Agelas sp. (SS-162) from the Kerama Islands, Okinawa, has  
led to the isolation of the new bromopyrrole alkaloids, 2-bromokeramadine (93), 2-bromo-9, 
10-dihydrokeramadine (94), tauroacidins C (95) and D (96), and mukanadin G (97) (Figure 17) [53]. 
Of these bromopyrroles, only 2-bromokeramadine (93) shows (weak) activity against E. coli, although 
mukanadin G (97) has moderate antifungal activity (next section). The highly complex agelamadins  
A (98) and B (99) were also characterized in the Okinawan sponge Agelas sp. (SS-162) (Figure 18) [54]. 
Both bromopyrroles are active against B. subtilis (MIC, 16 µg/mL each) and Micrococcus luteus 
(MIC, 4.0 and 8.0 µg/mL, respectively). The related agelamadins C–E exhibit only antifungal activity 
as shown in the next section. 
The South China Sea sponge Acanthella cavernosa contains eight new chlorinated diterpenoids, 
kalihinols M–T (100–107) (Figure 18). In addition, seven previously isolated analogues were isolated [55]. 
Kalihinols O (102), P (103), Q (104), R (105), S (106), and T (107) exhibit significant antifouling 
activity against Balanus amphitrite larvae: EC50 1.43, 0.72, 1.48, 1.16, 0.53, and 0.74 µM, respectively. 
 
Figure 17. Cont. 
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Figure 17. Structures of bromopyrroles 93–99 from the sponge Agelas sp. (SS-162) [53,54]. 
 
Figure 18. Structures of kalihinols M–T (100–107) from the sponge Acanthella caverenosa [55]. 
While no new marinopyrroles were reported in the time frame for this review, it is important to cite 
an excellent survey of these antibacterial marine halogenated pyrroles [56] and an equally excellent report 
on their activity against methicillin-resistant S. aureus, including synthetic marinopyrrole analogues [57]. 
Like gorgonians and marine sponges, algae employ a chemical arsenal to prevent bacterial 
smothering (biofouling), and several examples of halogenated antibacterial compounds have been isolated 
from algae. 
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Figure 19. Structures of red algae metabolites 108–114 [58–60]. 
The prodigious organohalogen-producing red alga Asparagopsis taxiformis “limu kohu,” which is 
the favorate edible seaweed of native Hawaiians, and the source of more than 100 organohalogens [2,3], 
contains the unusual mahorone (108) and 5-bromomahorone (109) (Figure 19) [58]. Both compounds 
are highly toxic to the marine bacterium Vibrio fisheri (EC50 0.16 µM for both), and both are most 
active against the Gram-negative bacterium Acinebacter baumanni and lesser activity towards E. coli 
and S. aureus. The red alga Plocamiun angustum metabolite plocamenone (110) inhibits the growth of  
B. subtilis comparable to that of chloramphenicol (inhibition zone of 10 mm vs. 12 mm, respectively). 
Species of Laurencia red algae continue to reveal novel halogenated natural products. A Chinese 
collection of Laurencia okamurae yielded the three new laurokamins A–C (112–114)  
(Figure 19) [60], but only laurokamins B (113) and C (114) show (weak) activity against E. coli (6 mm 
inhibition diameter). 
Three omaezallenes (115–117) were isolated and characterized from a collection of Laurencia sp. 
from Omaezaki, Japan (Figure 20) [61]. Of the three metabolites, omaezallene (115) was the most 
active in an antifouling assay against the larvae of the barnacle Amphibalanus amphitrite (EC50  
0.22 µg/mL), but only weakly toxic to the larvae (LC50 4.8 µg/mL). The other metabolites have: 116, 
EC50 0.30 µg/mL, and 117, EC50 1.5 µg/mL. 
 
Figure 20. Structures of omaezallenes 115–117 from the red alga Laurencia sp. [61]. 
A collection of Formosan Laurencia brongniarii afforded the new polybrominated indole,  
4,5,6-tribromo-2-methylsulfinylindole (118) in addition to 11 known brominated indoles (Figure 21) [62]. 
Although 118 is inactive, of the known indoles, 119–121 show significant antibacterial activity against 
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Enterobacter aerogenes (ATCC 13048), Salmonella enteritidis (ATCC 13076), and Serratia marcescens 
(ATCC 25419). Several bromoditerpenes were characterized from the red alga, Sphaerococcus 
coronopifolius, living in the Berlenga Nature Reserve, Peniche, Portugal. These include the new 
sphaerodactylomelol (122) and the previous known sphaeranes 123–126 (Figure 21) [63]. Although no 
activity against E. coli (ATCC 25922) and Pseudomonas aeruginosa (ATCC 27853) is observed for 
122–126, sphaerodactylomelol (122), 123, and 125 are active against S. aureus (IC50 96.30, 22.42, and 
6.35 µM, respectively). 
 
Figure 21. Structures of bromoindoles 118–121 and bromosphaerols 122–126 [62,63]. 
The Fijian red alga Callophycus sp. has yielded five new bromophycoic acids A–E (127–131)  
(Figure 22) [64]. These new examples of diterpene-benzoate marine natural products possess a range 
of biological activities, including antibacterial. For example, all five compounds are active against 
methicillin-resistant S. aureus (MIC 1.6–6.3 µg/mL) with bromophycoic acid A (127) being 
comparable to vancomycin (1.6 vs. 2 µg/mL). Likewise, bromophycoic acids A and E are active 
against vancomycin-resistant Enterococcus facium (MIC 6.3 and 1.6 µg/mL, respectively). 
The ascidian Synoicum sp. collected from Korean waters was found to contain eudistomins Y2–Y7 
(132–137) (Figure 23) [65]. These known β-carbolines display a range of activity against both  
Gram-positive and Gram-negative bacteria (Table 3). This study also included the synthesis of several 
hydroxyl analogues via sodium borohydride reduction of the carbonyl group, but no improvement in 
antibacterial activity is observed. Although 132–137 were previously described, antibacterial activity 
was not reported [66]. 
Another examination of this ascidian from Korea has revealed the presence of nine new brominated 
furanones, cadiolides 138–142 and synoilides 143–146 (Figure 24) [67]. Cadiolides H and synoilides 
A and B are interconverting Z and E isomers. Simultaneously with this study, another group isolated 
cadiolide E (138) along with the related cadiolides C (147), D (148), and F (149) from the ascidian 
Pseudodistoma antinboja (Figure 24) [68]. Like the eudistomins (Table 3), the cadiolides display 
significant antibacterial activity against both Gram-positive and Gram-negative bacteria (Table 4). The 
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synoilides (143–146) show much weaker or no activity against these bacteria. Cadiolide F (149) and 
rubrolides P (150) and Q (151) also exist as interconverting Z and E isomers. 
 
 
Figure 22. Structures of bromophycoic acids A–E (127–131) from the red alga 
Callophycus sp. [64]. 
 
Figure 23. Structures of eudistomins Y2–Y7 (132–137) from the ascidian Synoicum sp. [65]. 
Table 3. Antibacterial activity of eudistomins Y2–Y7 (132–137) (MIC µg/mL) [65]. 
Bacterium Y2 (132) Y3 (133) Y4 (134) Y5 (135) Y6 (136) Y7 (137)
Staphylococcus aureus (ATCC 6538p) 50 12.5 3.125 6.25 1.56 3.125 
Bacillus subtilis (ATCC 6633) 25 12.5 0.78 3.125 1.56 0.78 
Micrococcus luteus (IFO 12708) 25 12.5 1.56 3.125 1.56 1.56 
Salmonella typhimurium (ATCC 14028) 50 6.25 0.39 0.78 0.39 0.78 
Proteus vulgaris (ATCC 3851) 25 6.25 0.39 1.56 0.78 0.78 
Escherichia coli (ATCC 35270) >100 >100 50 100 50 50 
Similar to the cadiolides are the rubrolides and, in addition to rubrolides P (150) and Q (151), four 
new examples were found in a South African Synoicum globosum ascidian, 3″-bromorubrolide F 
(152), 3′-bromorubrolide E (153), 3′-bromorubrolide F (154), and 3′,3″-dibromorubrolide E (155) 
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(Figure 25) [69]. The previously known non-brominated rubrolides E (156) and F (157) were also 
isolated from this animal, and all six rubrolides display varying degrees of antibacterial activity (Table 5). 
It is noted that 3′-bromorubrolide F (154) is identical to rubrolide Q (151). 
 
 
 
Figure 24. Structures of the cadiolides, synoilides, and rubrolides (138–151) from the 
ascidians Synoicum and Pseudodistoma antinboja [67,68]. 
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Table 4. Antibacterial activity of cadiolides E, G, H, and I (138–142, 147–149) and 
rubrolides P and Q (150, 151) (MIC µg/mL) [67,68]. 
Bacterium 138 139 140/141 142 147 148 149 150 151 
Staphylococcus aureus 3.1 3.1 6.3 0.8 0.4 6.3 12.5 50 50 
Bacillus subtilis 1.6 12.5 1.6 0.8 3.1 6.3 12.5 50 50 
Kocuria rhizophilia 0.8 3.1 3.1 0.8 – – – – – 
Salmonella enterica 1.6 0.8 3.1 1.6 – – – – – 
Proteus hauseri 3.1 3.1 3.1 6.3 – – – – – 
Escherichia coli >100 >100 >100 >100 – – – – – 
Staphylococcus 
epidermidis 
– –   0.4 0.8 6.3 50 25 
Kocuria rhizophila – –   0.2 1.6 3.1 6.3 3.1 
 
Figure 25. Structures of rubrolides 152–157 from the ascidian Synoicum globosum [69]. 
Table 5. Antibacterial activity of rubrolides 152–157 from the ascidian Synoicum 
globosum (IC50 µM) [69]. 
Bacterium 152 153 154 155 156 157 
MRSA a (ATCC BAA-1720) 256 82 360 89 105 1006
Staphylococcus epidermidis (ATCC 35984) 98 38 42 28 21 79 
Enterococcus faecalis (ATCC 700802) b 43 16 2 2 89 47 
Escherichia coli (0157:H7) b 22 0 14 25 16 15 
a Methicillin-resistant Staphylococcus aureus; b Gentamycin- and vancomycin-resistant; percent growth at  
100 µg/mL. 
The ascidian Synoicum pulmonaria from the Norwegian coast contains synoxazolidinones A (158) 
and C (159), and pulmonarins A (160) and B (161) (Figure 26) [70]. The two synoxazolidinones 
display broad activity against fouling marine species and 159 is comparable to the most active 
commercial antifouling product, Sea-Nine-211. In contrast, the pulmonarins prevent bacterial growth 
but have lower activity against microalgae and no activity towards barnacles (Table 6). In addition, several 
analogues were synthesized, but are generally less active than their natural counterparts. 
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Figure 26. Structures of synoxazolidinones A (158) and C (159), and pulmonarians A 
(160) and B (161) from the ascidian Synoicum pulmonaria [70]. 
Table 6. Adhesion growth inhibition of synoxazolidiones A (158) and C (159), and 
pulmonarin A (160) from the ascidian Synoicum pulmonaria [70] a. 
 156 159 160 161 
 Ad b Gr c Ad Gr Ad Gr Ad Gr 
Marine Bacteria 
Halomonas aquamarina 20 – – 2 3 – – – 
Polaribacter irgensii – 20 20 2 – 0.2 – – 
Pseudoalteromonas elyakovii – 0.02 – 20 – 0.2 – – 
Roseobacter litoralis – 0.02 2 0.2 0.03 – 20 – 
Shewanella putrefaciens – 0.2 – 20 – – – – 
Vibrio aestuarians – 0.02 2 0.2 0.03 – 20 – 
Vibrio carchariae – 2 20 2 3 – 20 – 
Vibrio harveyi – – 2 0.02 – – – – 
Vibrio natriegens – 0.02 20 2 0.03 – 20 – 
Vibrio proteolylicus – 0.02 2 0.02 – – – – 
Microalgae 
Cylindrotheca closterium 20 20 2  0.2 – – – – 
Exanthemachrysis gayraliae 20 20 2  0.2 – – – – 
Halamphora coffeaeformis 20 20 2  2 30 – – – 
Pleurochrysis roscoffensis 20 20 2  2 – – – – 
Porphyridium purpureum – 20 0.2 0.02 – 0.2 – – 
Crustacean Settlement 
Balanus improvisus (IC50) 15  2  –  –  
a Inactive at ≥10 µg/mL; b Adhesion inhibition (MIC, µM); c Growth inhibition (MIC, µM). 
Several novel antibacterial organohalogen marine fungal metabolites have been discovered in recent 
years. The fungus Bartalinia robillardoides (strain LF550), which was isolated from the 
Mediterranean sponge Tethya aurantium, produces three novel chloroazaphilones, helicusin E (162), 
isochromophilone X (163), and isochromophilone XI (164) (Figure 27) [71]. Only isochromophilone 
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XI (164) shows antibacterial activity against B. subtilis (IC50 55.6 µM) and Staphylococcus lentus  
(IC50 78.4 µM), which is slightly less active than the previously known deacetylsclerotiorin, also 
isolated from this fungus. 
 
Figure 27. Structures of fungal metabolites 162–164 from the fungus Bartalinia 
robillardoides strain LF550 [71]. 
The deep-sea derived Spiromastix sp. fungus (collected at 2869 meters) has furnished 15 new 
spiromastixones A–O (165–179) (Figure 28) [72]. These novel chlorodepsidones display impressive 
antibacterial activity against the Gram-positive bacteria S. aureus (ATCC 29213), Bacillus 
thuringensis (SCS10 BT01), and B. subtilis (SCS10 BT01), but not against the Gram-negative E. coli 
(ATCC 25922). For example, spiromastixone J (175) has 0.125, 0.25, and 0.125 µg/mL, respectively, 
against the three Gram-positive bacteria. Moreover, 175 is strongly inhibitory towards MRSA, 
methicillin-resistant Staphylococcus epidermidis (MRSE), and vancomycin-resistant Enterococcus faecalis 
and E. faecium (VSE). Spiromastixones F–I (171–174) are also potent inhibitors of MRSA and MRSE, 
and are superior to levofloxacin. This activity increases with an increasing number of chlorines. 
 
Figure 28. Structures of spiromastixones A–O (165–179) from the fungus Spiromastix sp. [72]. 
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Marine bacteria also produce antibacterial compounds, including those that contain halogen. 
Merochlorins A–D (180–183) are novel meroterpenoids isolated from the marine bacterium 
Streptomyces sp. strain CNH-189 from a California coastal sediment (Figure 29) [73,74]. Both 
merochlorins A (180) and B (181) are active against MRSA (2–4 µg/mL), and 180 is active in vitro 
against Clostridium difficile. 
 
Figure 29. Structures of merochlorins A–D (180–183) from Streptomyces sp. CNH-189 [73,74]. 
Another California marine sediment contains Streptomyces strains CNQ-329 and CNH-070, which 
produce the six novel napyradiomycins A–F (184–189) (Figure 30) along with three previously known 
napyradiomycins B2–B4 (e.g., B3 = 190) [75]. Of these metabolites, napyradiomycins A (184) and B3 
(190) are the most active against MRSA (MIC 16 and 2 µg/mL, respectively). 
 
Figure 30. Structures of napyradiomycins A–F (184–189) from Streptomyces CNQ-329 
and CNH-070 [75]. 
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A Chinese collection of the marine-derived Streptomyces sp. SCS10 10428 has afforded the three 
new napyradiomycins 191–193, in addition to several known analogues, including napyradiomycins 
B1 and B3 (190) (Figure 31) [76]. Metabolites 191 and 192 are strongly active against S. aureus 
ATCC 29213 (MIC 4 and 0.5 µg/mL, respectively), and all three napyradiomycins are active against  
B. thuringiensis SCS10 BT01 and B. subtilis SCS10 BS01 (MIC 1–6 µg/mL). 
 
Figure 31. Structures of napyradiomycins 191–193 [76]. 
From a coastal sediment in Germany there was isolated the novel salimabromide (194), produced by 
the marine myxobacterium Enhygromxya salina (Figure 32) [77]. This structurally unusual compound 
has modest activity only against Arthrobacter cristallopoedes. 
 
Figure 32. Structure of salimabromide (194) from the marine myxobacterium 
Enhygromxya salina [77]. 
Cyanobacteria (blue-green algae) are prodigious producers of biologically active organohalogen 
natural products, and a collection of Leptolyngbya crossbyana found overgrowing on Hawaiian coral 
yielded the new honaucins A–C (195–197) (Figure 33) [78]. All three compounds inhibit quorum 
sensing against Vibrio harveyi BB120 (IC50 5.6, 17.6, and 14.6 µM, respectively), and to a lesser 
extent towards E. coli JB525. Interestingly, the synthetic brominated and iodinated analogues of 
honaucin A (195) are more active in quorum sensing inhibition than the natural honaucin A itself. A 
Guamanian cyanobacterium which is very similar to Lyngbya produces the novel biologically active 
lipids pitinoic acids A–C (198–200), which inhibit quorum sensing in the Gram-negative bacterium 
Pseudomonas aeruginosa (Figure 33) [79]. 
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Figure 33. Structures of honaucins A–C (195–197) from the cyanobacterium Leptolyngbya 
crossbyana [78], and pitinoic acids A–C (198–200) from a cyanobacterium [79]. 
3. Antifungal Activity 
In addition to their often potent antibacterial activity (vide supra), many marine sponges contain 
halogenated metabolites with powerful antifungal properties. The new tetramic acid glycoside, aurantoside 
K (201), was isolated from a Fijian sponge belonging to the genus Melophlus (Figure 34) [80]. 
Auranotoside K is a demethylated analogue of the previously known aurantoside I. Although devoid of 
antibacterial, antimalarial, and cytotoxicity in the assays examined, 201 displays broad antifungal activity 
towards Candida albicans (wild type ATCC 32354 and amphotericin-resistant ATCC 90873; MIC 
31.25 and 1.95 µg/mL, respectively), Cryptococcus neoformans, Aspergillus niger, Penicillium sp., 
Rhizopus sporangia, and Sordaria sp. The Indonesian sponge Theonella swinhoei has yielded the new 
aurantoside J (202), which is an epimer of the previously known auranotoside G (Figure 34) [81]. The 
new 202 differs from aurantoside G at the anomeric center C-1′ of the xylose sugar unit. Antifungal 
activity of 202 is negligible compared to that of aurantosides G and I. 
 
Figure 34. Structure of aurantoside K (201) from the sponge Melophlus sp. [80] and 
aurantoside J (202) from the sponge Theonella swinhoei [81]. 
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A Red Sea specimen of Theonella swinhoei contains the antifungal glycopeptide theonellamide G 
(203) (Figure 35), which is very similar to the known theonellamide A, lacking only a methyl group on 
the p-bromophenylalanine and a hydroxyl group in the α-aminoadipic acid group [82]. Theonellamide 
G shows potent antifungal activity against both wild and amphotericin B-resistant strains of Candida 
albicans; IC50 4.49 and 2.0 µM, respectively. The positive control amphotericin B had 1.48 µM against 
the wild type Candida albicans. 
 
Figure 35. Structure of theonellamide G (203) from the sponge Theonella swinhoei [82]. 
The New Zealand sponge Hamigera tarangaensis has yielded a suite of new hamigerans (204–211) 
(Figure 36), in addition to several known related hamigerans [83]. Hamigeran G (205) also exists as an 
enol tautomer, and hamigeran F (204) undergoes what appears to be an acid-catalyzed retro-aldol 
transformation (observed in a CDCl3 solution of 204). Hamigeran G selectively inhibits the growth of 
two strains of the yeast Saccharomyces cerevisiae. 
 
 
Figure 36. Structures of hamigerans 204–211 from the sponge Hamigera tarangaensis [83]. 
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The indolo[3,2-a]carbazole 72 from the deep-water sponge Asteropus sp. is antifungal towards 
Candida albicans (MIC 25 µg/mL), but 73 is not [48]. Similarly, purpuroine D (61) is active against  
C. albicans (IC50 19.03 ± 0.12 µg/mL), and purpuroines A (59), C (60), and D (61) inhibit the human 
disease-causing Aspergillus fumigates (IC50 28.58 ± 0.52, 26.07 ± 0.55, 25.56 ± 0.44 µg/mL, 
respectively) [46]. The previously cited nakijinamine A (79) shows antifungal activity towards  
C. albicans (IC50 0.25 µg/mL), Cryptococcus neoformans (IC50 0.5 µg/mL), and Trichophyton 
mentagrophytes (IC50 0.25 µg/mL). Less activity against C. albicans is seen with nakijinamines B (80) 
and F (81) (IC50 8 µg/mL each) [50]. The Agelas sponge metabolites, agelasines O (86), P (87), Q (88), 
R (89), and T (91) show varying degrees of activity against the fungi C. albicans, Aspergillus niger, 
Trichophyton mentagrophytes, and Cryptococcus neoformans, with the greatest activity towards the 
latter fungus by Q (88) and R (89) (IC50 8.0 µg/mL each) [52]. Similarly, these four fungi species are 
inhibited by the Agelas bromopyrroles 93–97, especially mukanadin G (97) against C. albicans and 
Cryptococcus neoformans (IC50 16 and 8.0 µg/mL, respectively) [53]. In addition to the Agelas sp. 
sponge metabolites agelamadins A (98) and B (99) [54], the new agelamadins C–E (212–214)  
(Figure 37) are also present in this sponge [84]. Antifungal activity is displayed against Cryptococcus 
neoformans by agelamadins A (98), B (99), C (212), and E (214) (IC50 8.0, 4.0, 32, 32 µg/mL, 
respectively [54,84]. 
 
Figure 37. Structures of agelamadins C–E (212–214) from the sponge Agelas sp. SS-162 [84]. 
Further examination of Agelas spp. (SS-162 and SS-156) sponges from Okinawa reveals the  
presence of nagelamides U–W (216–218) [85], X–Z (219–221) [86], 2-debromonagelamide U (222),  
2-debromomukanadin (223), and 2-debromonagelamide P (224) [87] (Figure 38). Antifungal activity 
against several fungi is summarized in Table 7, for which nagelamide Z (221) shows significant 
activity towards all four fungi. 
Marine algae can exhibit antifungal activity and several recent examples are described. The red  
alga Laurencia composita, collected from Pingtan Island, China, has afforded novel chamigranes, the 
laurecomins A–D (225–228) (Figure 39) [88]. Of these, laurecomin B (226) is antifungal towards 
Colletotrichum lagenarium (inhibitory diameter of 10 mm). 
A collection of Laurencia okamurai from Nanji Island, China, has furnished several new 
brominated sesquiterpenes, seco-laurokamurone (229), laurepoxyene (230), 3β-hydroperoxyaplysin 
(231), 3α-hydroperoxy-3-epiaplysin (232), 8,10-dibromoisoaplysin (233), and laurokamurene D (234)  
(Figure 40) [89]. Antifungal activity of 230–233 is tabulated in Table 8. 
  
Mar. Drugs 2015, 13 4068 
 
 
 
Figure 38. Structures of nagelamides U–Z (216–221) and 222–224 from Agelas spp. 
sponges [85–87]. 
Table 7. Antifungal activity of nagelamides U–Z (216–221) and 222–224 [85–87]. 
 Compound (IC50 µg/mL) 
Fungus 216 218 219 220 221 222 223 224
Candida albicans 4 4 2.0 2.0 0.25 – – – 
Trichophyton mentagrophytes – – 16 <32 4.0 16 – 32
Cryptococcus neoformans – – <32 <32 2.0 32 32 – 
Aspergillus niger – – 32 <32 4.0 – – – 
 
Figure 39. Structures of laurecomins A–D (225–228) from the red alga Laurencia composita [88]. 
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Figure 40. Structures of brominated sesquiterpenes 229–234 from the red alga Laurencia 
okamurai [89]. 
Table 8. Antifungal activity of brominated sesquiterpenes 230–233 from the red alga 
Laurencia okamurai [89]. 
 Compound a 
Fungus 230 231 232 233 Amphotericin B b Fluconazole b 
Cryptococcus neoformans (32609) >64 4 8 >64 1 1 
Candida glabrata (537) 2 4 >64 >64 2 1 
Trichophyton rubrum  32 16 >64 >64 1 >64 
Aspergillus fumigatus (07544) >64 >64 >64 >64 2 8 
a MIC50 µg/mL; b Positive controls. 
The red alga Symphyocladia latiuscula from the coast of Qingdao, China, is a rich source of 
brominated phenols, and several new examples have been discovered (235–245) (Figure 41) [90–92]. 
Bromocatechols 235, 242, and 244 display moderate activity against Candida albicans (MIC 37.5, 10, 
and 25 µg/mL, respectively) [90–92]. 
Weak antifungal activity is observed for gemmacolides T–Y (7–12) against Microbotryum 
violaceum and Septoria tritici, in the zone of inhibition ranging from 9.5–17 mm [31]. Two of the 
Synoicum sp. ascidian eudistomins, Y2 (132) and the non-brominated Y1, show potent to moderate 
activity against Candida albicans (MIC 6.25 and 50 µg/mL, respectively) [65]. The other eudistomins 
Y3–Y7 are inactive against the four fungal strains tested. A study of the bryozoan Chartella 
membranaceatruncata, collected in Kandalaksha Bay, the White Sea, resulted in the characterization 
of 2,4,7-tribromotryptamine (246) (Figure 42), which displays potent activity towards Candida 
albicans and Saccharomyces cereviseae, although this result was not quantified [93]. 
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Figure 41. Structures of symphyocladins A–G (236–242) and other bromophenols from 
the red alga Symphyocladia latiuscula [90–92]. 
 
Figure 42. Structure of 2,4,7-tribromotryptamine (246) from the bryozoan Chartella 
membranaceatruncata [93]. 
Several marine-derived bacteria have antifungal properties, such as strepchloritide B (47), from 
Streptomyces sp. OUCMDZ-1703, towards Candida albicans (13 ± 0.5 mm inhibitory diameter zone) [42], 
and the extraordinarily complex forazoline A (247), from Actinomadura sp. cultivated from the 
ascidian Ecteinascidia turbinata, towards Candida albicans (MIC 16 µg/mL) [94]. This unique marine 
polyketide is also active in vivo in a disseminated candidiasis model in mice, with no toxicity. This 
important antifungal compound may prove to be a clinical candidate to treat Candida albicans fungal 
infections in humans such as candidiasis, which affects some 400,000 people annually with a mortality 
rate of 46%–75% [95]. Indeed, fungal infections of all types cause 1.5 million deaths per year 
worldwide [96]. 
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Figure 43. Structure of forazoline A (247) from Actinomadura sp. [94]. 
The fungal metabolite isochromophilone XI (164), from Bartalinia robillardoides, is active against 
the fungus Trichophyton rubrum (IC50 41.5 µM), but not against Candida albicans and Septoria tritici [71]. 
The Baltic Sea cyanobacterium Anabaena cylindrica Bio33, cultivated in the laboratory, has provided 
the antifungal lipopeptides balticidins A–D (248–251) (Figure 44) [97,98]. These complex metabolites 
are active towards Candida maltosa with inhibition zones for balticidins A–D of 12, 15, 9, and 18 mm, 
respectively [97]. Antifungal activity with these compounds is also observed against C. albicans, 
Candida krusei, Aspergillus fumigatus, Microsporum gypseum, Mucor sp., and Microsporum canis. No 
antibacterial activity is observed for these compounds. 
 
Figure 44. Cont. 
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Figure 44. Structures of balticidins A–D (248–251) from the cyanobacterium Anabaena 
cylindrica Bio33 [97,98]. 
4. Antiparasitic Activity 
The parasitic diseases malaria, leishmaniasis, echinococcus, Chagas disease (American 
trypanosomiasis), onchocerciasis (“river blindness”), dracunculiasis (“guinea worm disease”), 
trypanosomiasis (“sleeping sickness”), schistosomiasis, lymphatic filariasis (elephantiasis), and others 
in tropical and sub-tropical regions put billions of people at risk and account for millions of illnesses 
and deaths annually [99–104]. The need for new drugs to combat these parasite vectors is paramount, 
and a number of newly isolated halogenated marine natural products display antiparasitic activity. 
A study of the Australian sponge Pseudoceratina sp. has yielded the new psammaplysin H (252) in 
addition to the known psammaplysins G (253) and F (254) (Figure 45) [104]. Compared to the latter 
two metabolites, 252 displays potent in vitro antimalarial activity against the chloroquine-sensitive 
(3D7) line of Plasmodium falciparum (IC50 (µM), 252: 0.41 ± 0.1; 253: 5.22 ± 1.6; 254: 1.92 ± 1.1), 
and minimal toxicity towards the mammalian cell lines HEK293 and HepG2, relative to 253 and 254 
(selectivity index ≥97). 
 
Figure 45. Structures of psammaplysins H (252), G (253), and F (254) from the sponge 
Pseudoceratina sp. [104]. 
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The Balinese sponge Aplysinella strongylata is the repository of 21 new psammaplysins (255–275) 
and six previously known analogues (Figure 46) [105]. Of those compounds tested (255, 256, 258, 
259, 263, 269, and 273) against the 3D7 Plasmodium falciparum parasite, 19-hydroxypsammaplysin E 
(255) displays the highest activity (IC50 6.4 µM). 
A collection of the sponge Suberea ianthelliformis has yielded five new bromotyrosines, araplysillin 
N20 formamide (276), araplysillin N20 formamide N-oxide (277), and araplysillins IV–VI (278–280) 
(Figure 47) in addition to 13 known brominated analogues [106]. Of the new metabolites, 276 and 277 
show moderate activity against both chloroquine-resistent (FcB-1) strain of Plasmodium falciparum 
(IC50 3.6 and 5.0 µM, respectively) and the chloroquine-sensitive (3D7) strain (IC50 7.0 and  
4.1 µM, respectively). 
 
 
Figure 46. Cont. 
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Figure 46. Structures of psammaplysins 255–275 from the sponge Aplysinella  
strongylata [105]. 
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Figure 47. Structures of araplysillins 276–280 from the sponge Suberea ianthelliformis [106]. 
A specimen of Verongula rigida from the coast of Columbia has afforded nine previously known 
bromotyrosines, and two of these, purealidin B and 11-hydroxyaerothionin, display selective antiparasitic 
activity at 10 and 5 µM against Leishmania panamensis and Plasmodium falciparum parasites, 
respectively [107]. The Australian sponge Iotrochota sp. contains the two antitrypanosomal 
compounds, iotrochamides A (281) and B (282) (Figure 48). Both compounds exhibit moderate 
activity against Trypanosoma brucei brucei (IC50 3.4 and 4.7 µM, respectively) [108]. 
 
Figure 48. Structures of iotrochamides A (281) and B (282) from the sponge Iotrochota sp. [108]. 
Another Australian marine sponge, Zyzzya sp., has furnished the new tsitsikammamine C (283),  
along with six previously known structurally related brominated alkaloids (Figure 49) [109]. This 
novel bispyrroloiminoquinone displays extraordinarily potent in vitro antimalarial activity towards 
both chloroquine-sensitive (3D7) and chloroquine-resistant (Dd2) Plasmodium falciparum with values 
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of IC50 13 and 18 nM, respectively. The selectivity index against HEK293 cells is >200. Known 
alkaloids makaluvamines J, G, and L are slightly less active than tsitsikammamine C in both screens. 
 
Figure 49. Structure of tsitsikammamine C (283) from the sponge Zyzzya sp. [109]. 
A suite of new manadoperoxides E–K (284–290) and peroxyplakoric ester C (291) were isolated 
from the sponge Plakortis cfr. lita (Figure 50), two of which contain chlorine (289, 290), in addition to 
several known manadoperoxides [110]. Manadoperoxides I (288) and K (290) display the greatest 
activity of the new compounds tested against Trypanosoma brucei rhodesiense (IC50 0.062 and  
0.087 µg/mL, respectively) and Leishmania donovani (IC50 0.633 and 1.89 µg/mL, respectively). 
However, the known manadoperoxide B has IC50 values of 0.003 and 0.589 µg/mL, respectively. 
 
Figure 50. Structures of manadoperoxides E–K (284–290) and peroxyplakoric ester C 
(291) from the sponge Plakortis cfr. lita [110]. 
The previously described bromophycoic acids (127–131) display activity against the malaria 
parasite (3D7 strain) Plasmonium falciparum, with the peroxy bromophycoic acid C (129) being the 
most active: IC50 8.7 µM [64]. For comparison, the known macrolide bromophycolide A shows IC50 
0.5 µM [111] and the positive controls chloroquine and artemisin show IC50 0.0058 and 0.0062 µM, 
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respectively [64]. The New Zealand ascidian Pseudodistoma opacum contains four new brominated  
β-carboline alkaloids, (–)-7-bromohomotrypargine (292) and opacalines A–C (293–295) (Figure 51) [112]. 
Opacalines B and C show activity against several parasites (Table 9). Some non-brominated synthetic 
analogues have comparable antiparasitic activity. For example, debromoopacaline C shows IC50 7.7 µM 
against Trypanosoma brucei rhodesiense, a parasite that causes human African trypanosomiasis. 
 
Figure 51. Structures of 292 and opacalines A–C (293–295) from the ascidian 
Pseudodistoma opacum [112]. 
Table 9. Antiparasitic activity of opacalines B (294) and C (295) and positive controls (IC50 µM). 
 Compound 
Parasite 294 295 Melarsoprol Benznidazole Miltefosine Chloroquine
Trypanosoma brucei 
rhodesiense 
30 27 0.005 – – – 
Trypanosoma cruzi 86 107 – 1.8 – – 
Leishmania donovani 130 101 – – 0.53 – 
Plasmodium falciparum 2.5 4.5 – – – 0.28 
The novel kororamide A (296) from the Australian bryozoan Amathia tortuosa, which exists as a 
mixture of interconverting amide rotamers (Figure 52), has activity against Plasmodium falciparum; 
70% growth inhibition at 20 µM for the chloroquine-sensitive strain, but only 50% growth inhibition 
of 50% at 20 µM for the chloroquine resistant strain [113]. 
 
Figure 52. Structure of kororamide A (296) from the bryozoan Amathia tortuosa [113]. 
A Panamanian cyanobacterium, Oscillatoria sp., has afforded the novel polyketide lactones 
coibacins A–D (297–300) (Figure 53) [114]. Activity of these compounds is seen against the parasite 
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Leishmania donovani axenic amastigotes, with coibacin A (297) being the most active, showing IC50 
2.4 µM. The coibacins were inactive to malaria and Chagas’ disease. 
 
Figure 53. Structures of coibacins A–D (297–300) from the cyanobacterium Oscillatoria sp. [114]. 
5. Antiviral Compounds 
In addition to harmful bacteria, fungi, and parasites, humans have to contend with lethal viruses, 
and the search for new antiviral compounds is intense. Although fewer in number than terrestrial 
sources, the marine environment has produced some antiviral active compounds. A review of antiviral 
lead compounds from sponges has appeared [115].  
A collection of 11 well-known bromotyrosines that was isolated from the Columbian sponges 
Verongula rigida [107,116] and Aiolochoria crassa [117] were examined for in vitro inhibition of 
HIV-1 replication [118]. Of these 11, six inhibit HIV-1 replication at different steps. Aeroplysinin-1, 
purealidin B, and 3-bromo-5-hydroxy-O-methyltyrosine inhibit the HIV-1 replication in a  
dose-dependent fashion, with a median maximum inhibition percentage of 74% at 20 µM and 47% at 
80 µM (not cytotoxic at these concentrations). Aeroplysinin-1, 19-deoxyfistularin 3, purealidin B, 
fistularin 3, and 3-bromo-5-hydroxy-O-methyltyrosine efficiently inhibit the nuclear import. In 
addition, aeroplysinin-1, purealidin B, fistularin 3, 3-bromo-5-hydroxy-O-methyltyrosine, and  
3,5-dibromo-N,N,O,O-tetramethyltyraminium inhibit X4 HIV-1 cell entry with an inhibition median 
percentage maximum of 2%–30% [118]. 
The marine-derived fungus Humicola fuscoatra has yielded three new chlorine-containing 
resorcyclic acid lactones, radicicols B–D (301–303) (Figure 54), in addition to the known radicicol  
(=monorden) and pochonins B, D, and N [119]. Of the three new radicicols, radicicol B (301) is the 
most active in the latent HIV-1 reactivation assay (25%; EC50 24.9 µM), but inferior to radicicol (98%; 
EC50 9.1 µM), pochonin B (98%; EC50 39.6 µM), and pochonin C (92%; EC50 6.3 µM). Those 
compounds lacking a conjugated carbonyl (Michael acceptor) are inactive. 
  
Mar. Drugs 2015, 13 4079 
 
 
 
Figure 54. Structures of radicicols B–D (301–303) from Humicola fuscoatra [119]. 
Mangrove plants that grow in tropical and subtropical intertidal estuarine zones are a rich source of 
natural products including organohalogens [120]. The Chinese mangrove plant Aegicerus corniculatum 
has an associated fungus, Emericella sp., that produces six new isoindolones, emerimidines A (304) 
and B (305), and emeriphenolicins A–D (306–309) (Figure 55) [121]. Of this collection only the  
non-halogenated emerimidines A and B display antiviral activity towards influenza A virus (H1N1) 
replication in MDCK cells (IC50 42.07 and 62.05 µg/mL, respectively; ribavirin positive control:  
24.60 µg/mL). 
 
Figure 55. Structures of emerimidines A (304) and B (305), and emeriphenolicins A–D 
(306–309) [121]. 
The Indian Ocean ascidian Synoicum sp. has yielded the new rubrolide R (310) and the known 
rubrolide A (311) (isolated as the diacetates), along with the known cadiolide B (312) and prunolide A 
(313) (Figure 56) [122]. The latter two metabolites are active against the Japanese encephalitis virus at 
a concentration of 1 µg/mL. 
Mar. Drugs 2015, 13 4080 
 
 
 
Figure 56. Structures of 310–313 from the ascidian Synoicum sp. [122]. 
The marine cyanobacterium Trichodesmium erythraeum, collected in Singapore, has afforded the  
new aplysiatoxins, 3-methoxyaplysiatoxin (314) and 3-methoxydebromoaplysiatoxin (315) (Figure 57), 
in addition to the known aplysiatoxin, debromoaplysiatoxin, and anhydrodebromoaplysiatoxin [123]. 
Both 315 and anhydrodebromoaplysiatoxin display significant activity against the Chikungunya virus 
(CHIKV) in infected baby hamster kidney cells (BHK21), with EC50 values of 2.7 and 22.3 µM, 
respectively. Debromoaplysiatoxin is the most potent of these five compounds with EC50 1.3 µM. The 
two brominated metabolites did not result in any significant inhibition at 10 µM. 
 
Figure 57. Structures of aplysiatoxins 314 and 315 from the cyanobacterium 
Trichodesmium erythraeum [123]. 
Of several known polybromocatechols isolated from the Korean red alga Neorhodomela aculeata, 
lanosol (316) and 317 are active against the human rhinovirus HRV2, IC50 2.50 and 7.11 µg/mL, 
respectively. The latter polybrominated diphenylmethane is also active towards HRV3, IC50 4.69 µg/mL 
(Figure 58) [124]. The naturally occurring algae (Peyssonnelia sp.) and sponge (Hyatella intestinalis) 
metabolite peyssonol A (318) (Figure 58) has been evaluated, along with synthetic stereoisomers, 
against a recombinant HIV-1 strain (Rep-Rlue Sac II) [125]. Peyssonol A shows the most activity 
(EC50 1 µM), with analogues 319–321 somewhat less active (IC50 2–4 µM). 
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Figure 58. Structures of lanosol (316) and 317 from the red alga Neorhodomela  
aculeata [124] and peyssonol A (318) and synthetic analogues 319–321 [125]. 
6. Antitumor Compounds 
Of enormous concern to all mankind is cancer—the inexorable transformation of normal cells and 
the proliferation of cancerous cells into tumors. The marine environment provides an array of 
metabolites active against cancer cells. 
Amongst all marine life, sponges have afforded the vast majority of anti-tumor compounds. The 
Vietnamese sponge Penares sp. contains the novel alkaloids, 322 and 323 (Figure 59), the former of 
which is moderately cytotoxic to the human tumor cell lines HL-60 (lung) and HeLa (cervix), IC50 16.1 
and 33.2 µM, respectively, whereas 323 is inactive [126]. 
 
Figure 59. Structures of 322 and 323 from the sponge Penares sp. [126]. 
The novel polyketides, PM050489 (324) and PM060184 (325), were isolated from the Madagascan 
sponge Lithoplocamia lithistoides (Figure 60) [127]. Both are tubulin-binders, and show excellent 
growth inhibition against human tumor cells, including HT-29 (colon), A-549 (lung), and MDA-MB-231 
(breast), with GI50 values of 0.46, 0.38, and 0.45 (324) and 0.42, 0.59, and 0.71 (325) nM, respectively. 
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Figure 60. Structures of PM050489 (324) and PM060184 (325) from the sponge 
Lithoplocamia lithistoides [127]. 
The new sesterterpenoid phobaketals N (326) (Figure 61) isolated from a Korean Phorbas sp. 
sponge has potent cytotoxicity against the human pancreas cell line (Panc-1) and the human renal cell 
lines (A498 and ACHN) with IC50 11.4, 18.7, and 24.4 µM, respectively [128]. Of the two 
nonbrominated phorbaketals (L and M) also isolated from this sponge, only phorbaketal L shows 
cytotoxicity (A498, 17.3 µM). 
 
Figure 61. Structure of phorbaketal N (326) from the sponge Phorbas sp. [128]. 
A Micronesian specimen of a Suberea sp. sponge has afforded four new psammaplysins (327–330) 
and four new ceratinamines (331–334) (Figure 62), along with nine previously known bromotyrosine 
analogues [129]. Whereas the ceratinamines are essentially devoid of cytotoxicity against a panel of 
human cancer cell lines, the psammaplysins are quite active (Table 10). Included in the table are some 
of the isolated known analogues and the positive control doxorubicin. 
Two new brominated acetylenes, 335 and 336, were isolated from a collection of Haliclona sp. 
sponge living in Saudi Arabia waters (Figure 63) [130]. Both are active towards MCF-7 human breast 
cancer cells, IC50 32.5 and 50.8 µM, respectively, but not against HepG2 (human hepatocellular 
carcinoma), WI-38 (skin carcinoma), and Vero (African green monkey kidney). 
Callyspongiolide (337) is a novel macrolide characterized from the Indonesian sponge Callyspongia sp. 
(Figure 64) [131]. This metabolite exhibits potent cytotoxicity against L5178Y mouse lymphoma cells, 
human Jurkat J16 T and Ramos B lymphocytes with IC50 values of 320, 70, and 60 nM, respectively. 
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Figure 62. Structures of psammaplysins 327–330 and ceratinamines 331–334 from the 
Suberea sp. sponge [129]. 
Table 10. Growth inhibition (GI50 µM) of psammaplysins and known analogues against 
human cancer cell lines [129]. 
Compound HCT-15 PC-3 ACHN MDA-MB-21 NUGC-3 NIC-H23
psammaplysin X (327) 3.3 2.3 3.3 1.2 3.5 6.4 
10-hydroxypsammaplysin X (328) 3.5 2.1 2.5 0.8 4.0 3.5 
psammaplysin A 3.9 6.9 5.1 4.3 3.8 12.4 
psammaplysin B 4.0 2.7 1.6 0.53 2.5 3.7 
psammaplysin D 24 25 27 21 26 27 
psammaplysin E 7.4 3.7 10.3 3.9 4.0 7.0 
19-hydroxypsammaplysin E 3.8 1.4 2.3 0.51 2.3 3.6 
moloka’iamine >70 >70 >70 >70 >70 >70 
7-hydroxymoloka’iamine >70 >70 >70 >70 >70 >70 
ceratinamine >70 >70 >70 >70 >70 >70 
hydroxyceratinamine >70 >70 >70 >70 >70 >70 
doxorubicin 1.4 0.52 2.0 1.8 0.51 1.9 
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Figure 63. Structures of brominated acetylenes 335 and 336 from the Haliclona sp. sponge [130]. 
 
Figure 64. Structure of callyspongiolide (337) from the sponge Callyspongia sp. [131]. 
From a sponge of the Petrosiidae family were isolated two new macrolides, phormidolides B  
(338) and C (339) (Figure 65) [132], which are structurally related to the known phormidolide A and 
oscillariolide. The new macrolides display growth inhibition of these human cancer cell lines: A-549 
(lung), HT-29 (colon), and MDA-MB-231 (breast) with IC50 values for 338/339 of 1.4/1.3, 1.3/0.8, and 
1.0/0.5 µM, respectively. 
 
Figure 65. Structures of phormidolides B (338) and C (339) from a sponge of the 
Petrosiidae family [132]. 
The Bahamas sponge Spirastrella mollis contains mollenyne (340) (Figure 66), a highly cytotoxic 
chlorodibromohydrin towards HCT-116 (human colon cancer cells) with IC50 1.3 µg/mL [133]. The 
positive control etoposide has IC50 0.55 µg/mL. 
A collection of the sponge Theonella swinhoei from Japanese waters (Tanegashima, Kagoshima 
Prefecture) has provided bromotheoynic acid (341) (Figure 67) [134]. This new brominated C17 acetylenic 
acid inhibits the cell proliferation of U937 and HL60 (human leukemia), A549 and H1299 (human 
lung), and HEK293 (human embryonic kidney) with values of IC50 24, 27, 58, 72, and 40 mg/mL, 
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respectively. Bromotheoynic acid also inhibits the maturation of starfish (Asterina pectinifera) oocytes at a 
concentration of 100 ng/mL. 
 
Figure 66. Structure of mollenyne (340) from the sponge Spirastrella mollis [133]. 
 
Figure 67. Structure of bromotheoynic acid (341) from the sponge Theonella swinhoei [134]. 
The sponge Stylissa sp. from the Derawan Islands in Indonesia has yielded four new brominated 
alkaloids, 342–345 (Figure 68), along with eight known analogues, including 346–353 [135]. All 
compounds were screened for their cytotoxicity towards mouse lymphoma cells L5187Y (Table 11), 
but only 342, 348, 350, and 351 show strong activity in this screen. The presence of an N-methyl and a 
carbonyl group in the imidazole ring increases activity (342 vs. 346; and 350/351), and the presence or 
absence of bromine may not always have a positive influence on the activity (346 vs. 347). 
 
Figure 68. Structures of brominated alkaloids 342–353 from the sponge Stylissa sp. [135]. 
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Table 11. Cytotoxicity of brominated alkaloids 342–353 against mouse lymphoma cells 
L5187Y [135]. 
Alkaloid L5178Y% of Inhibition Concentration (10 µg/mL) EC50 
342 86.1 3.5 
343 8.1 – 
344 10.2 – 
345 6.6 – 
346 7.5 – 
347 15.1 – 
348 89.3 9.0 
349 1.7 – 
350 99.6 1.8 
351 101.0 2.1 
352 9.0 – 
353 33.8 – 
Kahalalide F (control) – 6.3 
An examination of the Thai sponge Smenospongia sp. gathered in the Andaman Sea has uncovered 
the novel 6′-iodoaureol (354) and the bromoindoles 355–359 (Figure 69), isolated from a natural 
source for the first time, along with several other known natural products [136]. The new compounds, 
354–359, and the known 360–362 were screened against a battery of human cell lines for cytotoxicity 
(Table 12). Only 5,6-dibromotryptamine (362) shows good activity against MOLT-3 (human 
leukemia) and HeLa cells, with non-halogenated aureol (360) and 355 showing some modest 
cytotoxicity against HL-60 and HeLa, respectively. 
 
Figure 69. Structures of 6′-iodoaureol (354), aureol (360), and indoles 355–362 from the 
sponge Smenospongia sp. [136]. 
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Table 12. Cytotoxicity of 354–362 against human cancer cells (IC50 µM) [136]. 
Compound MOLT-3 HepG2 A549 HuCCA-1 HeLa HL-60 MDA-MB-231 
354 39.8 44.7 68.2 63.6 61.4 43.2 44.7 
355 >100 36.1 >100 >100 13.0 >100 >100 
357 >100 >100 >100 >100 >100 >100 >100 
358 >100 >100 >100 >100 69.3 – >100 
359 >100 >100 >100 >100 69.3 – >100 
360 24.8 29.2 76.4 87.6 62.1 14.6 29.7 
361 73.2 >100 >100 >100 7.81 64.3 >100 
362 5.4 23.1 78.6 23.6 9.4 – 34.1 
Etoposide 0.03 – – – – 1.18 – 
Doxorubicin – 0.69 0.43 0.69 0.38 – 0.62 
Two studies of the chemical content of the Caribbean sponge Smenospongia aurea, collected in the 
Bahamas along the coast of Little Inagua, has led to the chlorinated smenamides A (363) and B (364), 
and smenothiazoles A (365) and B (366) (Figure 70) [137,138]. Whereas the smenamides exhibit 
selectivity and nanomolar cytotoxic activity towards Calu-1 (lung) cancer cells, the smenothizoles are 
equally active and selective against A2780 (ovarian) cancer cells. 
 
Figure 70. Structures of smenamides A (363) and B (364), and smenothiazoles A (365) 
and B (366) from the sponge Smenospongia aurea [137,138]. 
The first naturally occurring trimeric hemibastadin, sesquibastadin 1 (367), was characterized from 
the sponge Ianthella basta, found in Ambon, Indonesia (Figure 71) [139]. The known bastadins 3, 6, 7, 
11, and 16 were also isolated. Whereas sesquibastadin 1 does not display cytotoxicity against L5178Y 
cells (mouse lymphoma), bastadins 6, 7, 11, and 16 do inhibit cell proliferation, with IC50 values of 
1.5, 5.3, 3.7, and 1.9 µM, respectively. However, sesquibastadin 1 is a potent protein kinase inhibitor 
as seen in a later section. 
Mar. Drugs 2015, 13 4088 
 
 
 
Figure 71. Structure of sesquibastadin 1 (367) from the sponge Ianthella basta [139]. 
The Red Sea sponge Pseudoceratina arabica from Hurghada at the Egyptian coast contains the  
new ceratinines A–E (368–372) (Figure 72), in addition to several known brominated alkaloids [140]. 
Screening of all isolated compounds against the highly metastatic MDA-MB-251 human breast cancer 
cell line reveals that only the known subereamolline A (373) is highly active, showing IC50 1.7 µM. 
 
Figure 72. Structures of ceratinines A–E (368–372) and subereamolline A (373) from the 
sponge Pseudoceratina arabica [140]. 
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An Australian version of Pseudoceratina verrucosa has furnished the new pseudoceralidinone  
A (374) and aplysamine 7 (375) (Figure 73), in addition to the known aerophobin 2, fiscularin 2, and 
fistularin 3 (not shown) [141]. Of these five bromotyrosines, only aplysamine 7 (375) shows 
cytotoxicity towards PC3 (prostate) cancer cells with IC50 4.9 µM. All five compounds are inactive 
against HeLa (cervical) and NFF (human neonatal foreskin fibroblast) cells (IC50 > 10 µM). 
 
Figure 73. Structures of pseudoceralidinone A (374) and aplysamine 7 (375) from 
Pseudoceratina verrucosa [141]. 
The South China Sea sponge Acanthella cavernosa has afforded the new cavernenes A–D (376–379), 
kalihinenes E (380) and F (381), and kalihipyran C (382) (Figure 74), in addition to several known 
analogues [142]. These metabolites were screened against several human cancer cell lines (Table 13). 
Cavernenes A and B display modest cytotoxicity towards HCT-116, and cavernene D shows slight activity 
against all five cell lines. The other new compounds (378, 379, 381, 382) are inactive across the board. 
 
Figure 74. Structures of cavernenes A–D (376–379), kalihinenes E (380) and F (381) and 
kalipyran C (382) from the sponge Acantella cavernosa [142]. 
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Table 13. Cytotoxicity of 376, 377, 380, and selected known analogues against human cell 
lines (IC50 µM) [142]. 
Compound HCT-116 A549 HeLa QGY-7701 MDA-MB-231 
376 6.31 >50 >50 >50 >50 
377 8.99 >50 >50 >50 >50 
380 14.36 >50 13.36 17.78 12.84 
kalihipyran A >50 13.09 11.19 13.53 >50 
15-formamido-kalihinene >50 17.53 14.74 16.39 >50 
10-formamido-kalihinene >50 6.98 13.30 14.53 6.84 
kalihinene X 12.25 8.55 10.59 13.02 7.46 
kalihinene Y >50 17.12 10.05 14.41 15.23 
camptothecin 9.25 2.32 6.98 4.05 0.50 
A number of known marine organohalogens were examined for possible cytotoxicity against cancer 
cell lines during the period covered by this review. To conserve space, their structures are not shown. 
A review of the antitumor activity of the Jaspis sponges is available [143]. The Fascaplysinopsis sp. 
sponge metabolite fascaplysin displays excellent cytotoxicity against chemoresistant SCLC (small cell 
lung cancer) cell lines, by multiple mechanisms [144]. Other cell lines are also discussed. The Suberea 
sp. sponge alkaloids ma’edamines A and B display significant cytotoxicity against COLO 205 (human 
colon cancer), MCF-7 (human breast cancer), and A549 (human lung) with IC50 values of 7.9/10.3, 
6.9/10.5, and 12.2/15.4 for ma’edamines A/B, respectively [145]. Synthetic analogues show activity 
against three breast cancer cell lines representing hormone receptor positive and HER2 positive breast 
cancer [146]. The bis-indole alkaloid 6″-debromohamacanthin A from a Spongosorites sp. sponge inhibits 
angiogenesis in human umbilical vascular endothelial cells and mouse embryonic cells [147]. The 
Pseudoceratina sp. alkaloids ceratamines A and B disrupt microtubule dynamics, which provides an 
explanation for their pronounced antimitotic activity (lower micromolar) [148]. The well known 
dibromo-dihydroxyoxocyclohexenyl acetonitrile has excellent activity against the K562 leukemia cell 
line (IC50 1.4 µg/mL) [149]. The known spirastrellolides A and B were isolated from the sponge 
Epipolasis sp. for the first time as free acids, and not as methyl esters. Both macrolides are cytotoxic to 
HeLa cells, with IC50 20 and 40 nM, respectively [150]. 
The previously cited dictyodendrins F–I (74–77) (Figure 14) are cytotoxic towards the SW620 
(human colon) cancer cell line with IC50 values of 8.5, 2.0, 16, and 10 µM, respectively. Dictyodendrin J 
is not cytotoxic. None of the five compounds is cytotoxic towards the multi-drug resistant variant 
SW620 Ad300 [49]. The kalihinols M–T (100–107) (Figure 18) were screened against several human 
cancer cell lines, along with some previously known kalihinols, and show weak to modest cytotoxicity 
(Table 14) [55]. 
The aforementioned new hamigerans F–J (204–208) (Figure 36) all show some degree of 
cytotoxicity towards HL-60 (human promyelocytic leukemia) with F (204), G (205), and 209 showing 
IC50 values of 4.9, 2.5, and 5.6 µM, respectively. The known hamigeran B is 3.4 µM [83]. The two most 
active hamigerans, G and B, share the same electrophilic 1,2-dione functionality. Of the three 
psammaplysins 252–254 (Figure 45), psammaplysin F (254) is moderately cytotoxic against the HepG2 
human carcinoma cell line (IC50 3.7 µM). Psammaplysins G (253) and H (252) show IC50 values of 
17.4 and >40 µM, respectively [104]. 
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Table 14. Cytotoxicity of kalihinols M–T (100–107) and related kalihinols against human 
cancer cell lines (IC50 µM) [55]. 
Kalihinol HCT-116 H1299 CT-26 
kalihinol O (102) 5.97 – – 
kalihinol P (103) 10.68 26.21 – 
kalihinol Q (104) 20.55 – – 
kalihinol R (105) 13.44 – – 
kalihinol E  18.31 – – 
kalihinol A 17.40 – – 
10-epi-kalihinol X 8.21 – – 
10-epi-kalihinol I 28.67 – – 
10-β-formamidokalihinol-A – – 28.82 
Red marine algae are also an excellent source of novel antitumor compounds with genus Laurencia in 
the limelight. A collection of Laurencia similis from the South China Sea has yielded the novel 
enantiomeric spiro-trisindoles similisines A (383) and B (383b), along with the new oxindole 384 
(Figure 75) [151]. The racemate 383 was separated into similisines A and B by enantioselective HPLC. 
All three compounds were screened against eight human cancer cell lines but only oxindole 384 shows 
(weak) activity against HL-60 (leukemia) and JURKA (leukemia) with values of IC50 35.06 and  
53.27 µM, respectively. 
 
Figure 75. Structures of similisines A (383a) and B (383b), and oxindole 384 from 
Laurencia similis [151]. 
An extensive examination of Laurencia viridis from the Canary Islands led to seven new 
brominated polyether triterpenoids, 15-dehydroxythyrsenol A (385), prethyrsenol A (386),  
13-hydroxyprethyrsenol A (387) [152], iubol (388), 22-hydroxy-15(28)-dehydrovenustatriol (389) [153], 
and saiyacenols A (390) and B (391) [154] (Figure 76), along with two new non-brominated analogues 
1,2-dehydropseudodehydrothyrsiferol and secodehydrothyrsiferol (not shown) [153]. These new 
oxasqualenoids were screened against several human cancer cell lines (Table 15). Jurkat cells are 
clearly the most sensitive to these brominated polyethers. The non-brominated secodehydrothyrsiferol 
shows IC50 2.5 µM in this assay. 
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Figure 76. Structures of polycyclic triterpenoids 385–391 from Laurencia viridis [152–154]. 
Table 15. Cytotoxicity of polycyclic triterpenoids 385–391 against human cancer cell lines 
(IC50 µM) [152–154]. 
Compound Jurkat a MM144 b HeLa c CAD-ES-1 
385 7.6 7.3 23.0 16.5 
386 8.2 10.2 29.0 14.5 
387 7.2 15.5 26.0 3.1 
388 3.5 13.0 27.0 11.0 
389 2.0 – 2.9 – 
390 7.8 27.0 27.5 25.5 
391 2.7 11.0 24.5 14.0 
a T-cell acute leukemia; b multiple myeloma; c cervical carcinoma; d Ewing’s sarcoma. 
The polybromoindoles from Laurencia brongniarii (Figure 21) were tested for cytotoxicity, but in 
this group only 2,4,5,6-tetrabromo-3-methylthioindole shows activity against Hep3B (liver carcinoma) 
and MCF-7 (breast carcinoma); IC50 7.7 and 10.5 µM, respectively. For comparison, the non-halogenated 
doxorubicin has values of IC50 1.2 and 1.5 µM, respectively. Other cell lines examined were HepG2, 
MDA-MB-231, and A549 [62]. Of the six new laurane-type sesquiterpenes from Laurencia okamurai 
(Figure 40), only 3β-hydroperoxyaplysin (231) and 3β-hydroxyaplysin show any cytotoxicity towards 
the A-549 cell line (IC50 35.3 and 15.4 µM, respectively. All other compounds are IC50 > 100 µM [89]. 
The known bis-(2,3-dibromo-4,5-dihydroxyphenyl)methane from Laurencia nana and Rhodomela 
confervoides displays significant growth inhibition against some cell lines (IC50 µg/mL): HeLa (17.6), 
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RKO (colon; 11.4), HCT-116 (colon; 10.6), BEL-7402 (hepatoma; 8.7), U87 (glioblastoma; 23.7), and 
HUVEC (vascular endothelial; 30.2). Moreover, this compound induces detachment of the cancer cells 
and apoptosis, and inhibits metastasis [155]. Although the Asparagopsis taxiformis cyclopentenones 
mahorone (108) and 5-bromomahorone (109) (Figure 19) are not cytotoxic towards several human 
cancer cell lines (A549, HepG2, HT29, and MCF7), mahorone is cytotoxic against healthy liver cells 
(54% growth inhibition at 5 µM) [58]. The bromoditerpene from Sphaerococcus coronopifolius, 
sphaerodactylomelol (122) (Figure 21), shows some cytotoxicity and anti-proliferative property against 
HepG-2 cells (IC50 720 and 280 µM, respectively). The known sphaerococcenol shows IC50 43 µM for 
anti-proliferative activity. For comparison, cisplatin and tamoxifen have IC50 values of 75 and 46 µM, 
respectively [63]. In contrast, bromophycoic acid E (131) from Callophycus sp. (Figure 22) shows 
cytotoxicity of IC50 6.8 µM as the mean value of 14 human cancer cell lines. The other bromophycoic 
acids are less active [64]. The South African Plocamium suhrii has provided the new halogenated 
monoterpenes 392 and 393 (Figure 77) and the known 394–398 [156]. These compounds were 
screened against the human esophageal cancer cell line WHCO1 with the following IC50 values (µM): 
392 (9.3), 393 (7.9), 394 (6.6), 395 (9.9), 396 (8.5), 397 (8.4), and 398 (15.1). For comparison, 
cisplatin has IC50 13 µM. Tetrachloro monoterpene 393 was previously isolated from Plocamium 
corallorhiza but not fully characterized [156]. 
 
Figure 77. Structures of halogenated monoterpenes from Plocamium suhrii [156]. 
The Synoicum sp. eudistomins Y2–Y7 (132–137) (Figure 23) were screened against A549 cancer 
cells, but only the previously known eudistomin Y9 shows cytotoxicity (IC50 17.9 µM) (doxorubicin 
has LC50 3.3 µM) [65]. Another known Synoicum sp. ascidian metabolite, prunolide A, is cytotoxic to 
breast cancer cell lines at <1 µM [122]. The newest member of the synoxazolidinone family of 
metabolites from Synoicum pulmonaria is synoxazolidinone C (399) (Figure 78), which is cytotoxic to 
several human cancer cell lines: A2058 (melanoma), MCF-7 (breast), and HT-29 (colon) at IC50 30.5 µM. 
This compound also kills normal lung fibroblast cells (MRC-5) at the same concentration [157]. 
 
Figure 78. Structure of synoxazolidinone (399) from the ascidian Synoicum pulmonaria [157]. 
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The tunicate Diazona cf formosa living off the coast of Timor Island, near Indonesia, has afforded 
the novel tanjungides A (400) and non-halogenated B (401) (Figure 79) [158]. Cytotoxicity of these 
bromoindoles was assayed against A549, HT29, and MDA-MB-231 human cancer cell lines. The data 
show that tanjungide A (400) is strongly active against the three cell lines: IC50 0.33, 0.19, and 0.23 µM, 
respectively. Tanjungide B is much less active (IC50 2.50, 2.31, and 1.63 µM, respectively). 
 
Figure 79. Structures of tanjungides A (400) and B (401) from the tunicate Diazona cf 
formosa [158]. 
The two new chlorinated didemnins 402 and 403 were isolated from the tunicate Trididemnum 
solidum from Little Cayman island along with the known nonchlorinated didemnins A (404) and B 
(405) (Figure 80) [159]. All four didemnins were evaluated for cytotoxicity against human cancer cells 
(Table 16), and all strongly inhibit cell proliferation in the cancer cell lines, especially didemnuns A 
and B, but not in the noncancerous VERO cell line. 
 
Figure 80. Structures of didemnins 402–405 from the tunicate Trididemnum solidum [159]. 
Table 16. Anti-cell proliferative activity of didemins 402–405 (IC50 µM) [159]. 
Didemnin SK-MEL a KB b BT-549 c SK-OV-3 d VERO e 
402 0.12 0.26 0.16 0.26 4.8 
403 0.06 0.42 0.16 0.38 2.08 
404 0.055 0.16 0.07 0.16 4.78 
405 0.022 0.09 0.02 0.1 0.15 
Doxorubicin 1.1 1.66 1.01 1.66 14 
a Melanoma; b epidermal carcinoma; c breast; d ovarian; e monkey kidney fibroblasts. 
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The Formosan soft coral Klyxum molle has afforded 11 new eunicellin-type diterpenoids, klymollins 
I–S (406–416) four of which, I–L, contain chlorine (Figure 81) [160]. Of the klymollins screened for 
cytotoxicity against the human cancer cell lines K562 myeloblastoid (leukemia), Molt-4 
(lymphoblastic leukemia), and T47D (breast carcinoma) only klymollin M (410) shows activity: ED50 
7.97, 4.35, and 8.58 µM, respectively. 
 
Figure 81. Structures of klymollins I–S (406–416) from the soft coral Klyxum molle [160]. 
The earlier discussed gemmacolides and dichotellides from the gorgonian Dichotella gemmacea 
(Figures 1 and 2) display some antitumor properties [30–34,161]. Against the human cancer cell lines 
A549 (lung adenocarcinoma) and MG63 (osteosarcoma), gemmacolides V (9) and Y (11) show IC50 
values of <1.5 and <0.3 µM, respectively, against A549; and gemmacolide Y has IC50 < 0.3 µM 
towards MG63. The positive control adriamycin gives IC50 2.8 and 3.2 µM for these two cell lines, 
respectively [31]. Juncin R shows 5.6 µM towards MG63 cells [30]. Of gemmacolides G–M, only 
gemmacolide J shows good growth inhibition against A549 cells (IC50 < 1.4 µM) [33]. The 
dichotellides F–U are not cytotoxic to the human cancer cell lines SW1990, MCF-7, HepG2, and H460 
cell lines, but dichotellide C displays (marginal) activity towards SW1990 (pancreatic) with IC50 45 µM 
(fluorouracil, IC50 121 µM) [34]. A later tour de force examination of Dichotella gemmacea revealed 
the presence of 18 new gemmacolides AA–AR (417–434) (Figure 82) [161]. The most cytotoxic 
compound in the A549 and MG63 cell line assays is gemmacolide AH (424) with IC50 for both cell 
types (adriamycin: IC50 2.8 and 3.2 µM). 
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Figure 82. Structures of gemmacolides AA–AR (417–434) from the gorgonian Dichotella 
gemmacea [161]. 
A study of the cochliomycins A–C (39–41) (Figure 5) reveals no cytotoxicity against A549 and 
HepG2 cancer cells, but the related LL-Z1640-1 shows modest activity; IC50 44.5 and 98.6 µM, 
respectively [37]. The structurally related resorcylic acid lactones, greensporones 435–448 (Figure 83) 
from the aquatic fungus Halenospora sp., were assayed for antitumor activity [162]. However, only 
greensporone C (439) shows significant cytotoxicity against the cell lines MDA-MB-435 (melanoma) 
and HT-29 (colon) with IC50 2.9 and 7.5 µM, respectively. 
The sponge-derived fungus Stachybotry sp. HH1 ZDDS1F1-2 has yielded several sesquiterpenoids 
and xanthones, totaling 15 compounds. In addition to the two new xanthones, stachybogrisephenones 
A (449) and B (450), the three known compounds grisephenone A (451), 452, and 453 are cytotoxic 
towards U937, HeLa, and K562 cell lines (Figure 84) [163]. Grisephenone A (451) has IC50 22.5 and 
14.6 µM towards U937 and HeLa cells, respectively. Compound 452 has IC50 22.3 and 14.0 µM 
against K562 and HeLa, respectively, and 453 shows IC50 7.2 µM against the HeLa cell line. 
In addition to the new griseofulvins 454 and 455, the mangrove-derived (Pongamia pinnata) fungus 
Nigrospora sp. MA75 has afforded the quinone 456, along with several known compounds (griseofulvins, 
xanthones, benzophenones) (Figure 85) [164]. Non-halogenated compound 456 is cytotoxic to these 
human cancer cell lines: MCF-7 (breast), SW1990 (pancreas), HepG2 (hepatocellular liver),  
NCI-H460 (lung), DU145 (prostate), and SMMC7721 (hepatocellular liver) with these respective IC50 
values (µg/mL): 4, 5, 20, 11, 17, and 7 µg/mL. For comparison, fluorouracil shows IC50 4, 16, 14, 1, 
0.4, and 2 µg/mL, respectively. 
Mar. Drugs 2015, 13 4097 
 
 
 
Figure 83. Structures of greensporones 435–448 from the freshwater aquatic fungus 
Halenospora sp. [162]. 
 
Figure 84. Structures of benzophenones 449–452 and xanthone 453 from Stachybotry sp. 
HH1 ZDDS1F1-2 [163]. 
 
Figure 85. Structures of 454–456 from the fungus Nigrospora sp. MA75 [164]. 
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The marine-derived Aspergillus sp. SCS10 FO63 fungus produces seven new averantin-type 
chlorinated anthraquinones 457–463 (Figure 86) along with five known analogues [165]. From this 
group, only 6-O-methyl-7-chloroaverantin (458) exhibits good cytotoxicity against SF-268 (glioblastoma), 
MCF-7 (breast), and NCI-H460 (lung) with IC50 values of 7.11, 6.64, and 7.42 µM, respectively. For 
comparison, cisplatin has IC50 values of 4.59, 10.23, and 1.56 µM, respectively. 
 
Figure 86. Structures of chlorinated averantin anthraquinones 457–463 from the fungus 
Aspergillus sp. SCS10 FO63 [165]. 
The Homaxinella sponge-derived fungus, Gymnascella dankaliensis, has furnished the new polyketide 
dankastatin C (464) (Figure 87) [166]. This compound displays pronounced cell growth inhibition of 
the murine P388 leukemia cell line with EC50 57 ng/mL (comparable to 5-fluorouracil with EC50  
78 ng/mL). 
 
Figure 87. Structure of dankastatin C (464) from the fungus Gymnascella dankaliensis [166]. 
The seagrass (Thalassia hemprichii)-derived fungi Polyporales PSU-ES44 and PSU-ES83 have yielded 
the new polyporapyranones A–H (465–472) (Figure 88), along with eight known analogues [167]. Of 
these compounds, only 465 shows moderate activity against Vero cells (IC50 6.93 µg/mL), and no 
polyporapyranone is active against MCF-7 cells. For comparison, ellipticine has IC50 1.28 µg/mL 
against these African green monkey kidney fibroblast (Vero) cells. 
A strain of the fungus Chaetomium globosum, which was obtained from the marine fish  
Mugil cephalus, has produced three new azaphilones, chaetomugilin S (473), dechloro-chaetomugilin 
A (chaetomugilin T) (474), and dechloro-chaetomugilin D (chaetomugilin U) (475) (Figure 89) [168]. 
Mar. Drugs 2015, 13 4099 
 
 
Chaetomugilin S (473) is modestly active towards these cell lines: P388, HL-60, L1210, and KB  
(IC50 46.0, 39.1, 43.7, and 34.5, respectively). 
 
Figure 88. Structures of polyporapyranones A–H (465–472) from the fungi Polyporales 
PSU-ES44 and PSU-ES83 [167]. 
 
Figure 89. Structures of chaetomugilins S, T, and U (473–475) from the fungus 
Chaetomium globosum [168]. 
Three new azaphilones, isochromophilones X–XII (476–478), have also been found in the fungus 
Diaporthe sp., which was isolated from the mangrove plant Rhizophora stylosa of Hainan Province, 
China (Figure 90) [169]. The familiar sclerotioramine and isochromophilone VI were also isolated. 
This is the first example of azaphilones being found in Diaporthe. Isochromophilone X (476) displays 
moderate cytotoxicity against MCF-7 (breast), SGC-7901 (gastric), SW1116 (colorectal), A549 (lung), 
and A375 (melanoma) with IC50 values of 14.90, 16.84, 24.15, 26.93, and 35.75 µM. The other azaphilones 
have >50 µM against these cell lines. 
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Figure 90. Structures of isochromophilones X–XII (476–478) from the fungus Diaporthe sp. [169]. 
A marine-derived Penicillium sp., which was isolated from seawater on the French coast, has 
yielded an analogue of fumagillin, ligerin (479) (Figure 91) [170]. Evaluation of ligerin against these 
cancer cell lines: KB (nasopharyngeal), AT6-1 (murine prostatic), POS1 and OSRGa (murine 
osteosarcoma), and L929 (murine fibroblasts) shows antiproliferative activity against all of these cell 
lines except KB cells. The highest activity of ligerin is seen in the POS1 cell line (IC50 117 nM), which 
is 20 times more active than the other cell lines. An Antarctic deep-sea fungus, Penicillium sp. PR19N-1, 
has yielded the four novel chlorine-containing sesquiterpenes 480–483 (Figure 91) [171]. The known 
non-chlorinated eremofortine C is also present. 
 
Figure 91. Structures of ligerin (479) and 480–483 from the fungi Penicillium spp. [170,171]. 
Cyanobacteria continue to be a major supplier of novel natural products, including halogenated 
metabolites. The freshwater cyanobacterium Nostoc sp. (UIC 10274) from Illinois has afforded the two 
new carbamidocyclophanes F (484) and G (485) (Figure 92) [172], both of which are antiproliferative 
against the human cancer cell lines MDA-MB-435 (breast) and HT-29 (colon) with IC50 0.5–0.7 µM 
for both 484 and 485. The cyanobacterium Fischerella sp. (SAG 46.79), a rich source of chlorinated 
indoles, contains the four new fischerindoles 486–489 (Figure 92) [173]. Of these four compounds 
only 487 (deschloro 12-epi-fischerindole I nitrile) shows (weak) cytotoxicity towards HT-29 cells 
(ED50 23 µM). Compounds 488/489 are the first carbazole-type fischerindoles to be discovered. 
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Figure 92. Structures of carbamidocyclophanes F (484) and G (485) from the cyanobacterium 
Nostoc sp., and fischerindoles 486–489 from the cyanobacterium Fischerella sp. [172,173]. 
Lyngbya genus is a prolific producer of organohalogens and the Taiwanese Lyngbya majuscule has 
afforded the known isomalyngamide A (490) and the new isomeric A-1 (491) (Figure 93) [174]. Both 
compounds are antiproliferative towards MCF-7 and MDA-MG-231 cells (IC50 4.6 and 2.8 µM, 
respectively, for 490), and they inhibit the migration of MDA-MB-231 cells (IC50 0.060 and 0.337 µM, 
for 490 and 491, respectively). Consistent with an antimetastatic mechanism for these isomalyngamides 
is that they both inhibit α-2,3-sialyltransferase (IC50 77.2 and 65.7 µM for 490 and 491, respectively). 
 
Figure 93. Structures of isomalyngamides A (490) and A-1 (491) from the cyanobacterium 
Lyngbya majuscule [174]. 
The new malyngamide 2 (492) was characterized from a Papua New Guinea collection of Lyngbya 
sordida (Figure 94) [175]. Cytotoxicity towards H-460 (lung) is modest at IC50 21 µM. The Red Sea 
Moorea producens (formerly Lyngbya majuscula) produces malyngamide 4 (493) (Figure 94), along 
with five known analogues [176]. This compound is weakly inhibitory to the human cancer cell lines 
MDA-MB-231, A549, and HT-29 (GI50 44, 40, and 50 µM, respectively). 
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Figure 94. Structures of malyngamides 2 (492) from Lyngbya sordida and 4 (493) from 
Moorea producens [175,176]. 
The previously presented coibacins A–D (297–300) from the Panamanian Oscillatoria sp. (Figure 53) 
show cytotoxicity against the H460 (lung) human cancer cell line, with coibacin D having the highest 
activity (IC50 11.4 µM) [114]. A collection of Moorea bouillonii from the Palmya Atoll in the Central 
Pacific Ocean has led to the discovery of five novel lyngbyabellins, 494–498 (Figure 95) [177]. 
Lyngbyabellin N (498) is very similar to the known lyngbyabellin H. Although 494–497 are inactive in 
the H-460 cytotoxicity screen, 498 shows a range of activity in this cell line, IC50 0.0048–1.8 µM, 
which may result from solubility difficulties in the assay medium. However, in the HCT-116 colon 
cancer cell line, 498 gives the reproducible and very potent IC50 40.9 ± 3.3 nM. 
 
Figure 95. Structures of lyngbyabellins 494–498 from the cyanobacterium Moorea 
bouillonii [177]. 
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Like terrestrial bacteria, marine bacteria can synthesize extremely complex natural products,  
most notably by marine-derived Streptomyces sp. A Bahamas marine sediment has provided  
Streptomyces variabillis (SNA-020) that produces ammosamide D (499) (Figure 96) [178]. This 
newest member of the ammosamide family has modest activity in the human cancer cell line MIA 
PaCa-2 (pancreas), IC50 3.2 µM. Similarly, a marine sediment from the San Clemente, California, 
coast has yielded chlorizidine A (500) (Figure 96) [179]. This metabolite, with the unprecedented  
5H-pyrrolo[2,1-a]isoindol-5-one ring system, is strongly cytotoxic to the human cell line HCT-116 
(colon), IC50 3.2–4.9 µM. 
 
Figure 96. Structures of Streptomyces sp. ammosamide D (499) and chlorizidine A (500) [178,179]. 
The earlier discussed strepchloritides A (46) and B (47) (Figure 7), from Streptomyces sp. 
OUCMDZ-1703, are cytotoxic against the MCF-7 (breast) cell line; IC50 9.9 and 20.2 µM,  
respectively [42]. The deep-sea derived Streptomyces sp. SCS10 03032 has provided the remarkable 
spiroindimicins A–D (501–504) (Figure 97) [180]. Spiroindimicin B (502) shows moderate activity 
against B16 (mouse melanoma), H460 (human lung), and CCRF-CEM (human leukemia): 5, 12, and  
4 µg/mL, respectively. Spiroindimicin C (503) towards HepG2 (human hepatocellular liver) and H460 
gives: 6 and 15 µg/mL, respectively. Spiroindimicin D (504) is slightly less active, and A (501) is 
inactive in all five cell lines, including MCF-7 (breast). For comparison, 5′-hydroxystaurosporine 
shows IC50 values of 8, 2, 8, and 5 µg/mL for HepG2, B16, H460, and CCRF-CEM, respectively. This 
same Streptomyces sp. contains indimicins A–E (505–509) and lynamicins F (510) and G (511) 
(Figure 97) [181]. Of this collection, only indimicin B (506) is cytotoxic to the MCF-7 cell line, IC50 
10.0 µM. No cytotoxicity is observed for the other indimicins when tested against SF268, MCF-7, 
H460, and HepG2. 
The aforementioned napyradiomycins 184–193 (Figures 30 and 31) [75,76] display antitumor 
activity towards the human colon cell line HCT-116 with these cytotoxicity values (IC50 µg/mL): 
napyradiomycin A (184) (4.19), B (185) (>20), C (186) (>20), D (187) (16.1), E (188) (4.81), F (189) 
(9.42), B2 (3.18), B3 (190) (0.19), and B4 (1.41) [75]. The effect of chlorine on the cytotoxicity is 
noteworthy (i.e., napyradiomycins A vs. B, and F vs. B2). A La Jolla, California, coastal sediment has 
afforded the actinomycete strain CNQ525, which produces the novel napyradiomycins 512–515 
(Figure 98) [182]. Assays of these compounds against the HCT-116 human colon cell line are as 
follows for the most active napyradiomycins (IC50 µM): CNQ525.538 (514) (6), B1 (2), B3 (190) (3), 
A80915A (3), A80915B (<1), and A809150 (<1). The etoposide control has 1 µM. 
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Figure 97. Structures of spiroindimicins A–D (501–504) and indimicins A–E (505–509) 
and lynamicins F (510) and G (511) from Streptomyces sp. SCS10 03032 [180,181]. 
 
Figure 98. Structures of napyradiomycins 512–515 from actinomycete strain CNQ525 [182]. 
The thermophilic bacterium Thermovibrio ammonificans, collected from the walls of a deep-sea 
hydrothemal vent on the East Pacific Rise, has provided two additional ammonificins, C (516) and D 
(517) (Figure 99) [183]. The ortho dibromophenyl ring is unique amongst natural organohalogens. 
Both ammonificins C and D induce apoptosis at 2 and 3 µM, respectively, in a standard apoptosis 
assay with W2 and D3 cells. 
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Figure 99. Structures of ammonificins C (516) and D (517) from Thermovibrio 
ammonificans [183]. 
Despite their bland appearance, bryozoans (“moss animals”) are the repository of incredibly 
complex natural products, many of which are heavily brominated. The Patagonian bryozoan 
Aspidostoma giganteum contains a wealth of such organobromines, the aspidostomides A–H (518–525) 
and aspidazide A (526) (Figure 100) [184]. The only cytotoxic member (IC50 < 10 µM) of this 
collection is aspidostomide E (522), which displays IC50 7.8 µM towards the human cell line 786-O 
(renal carcinoma). 
 
Figure 100. Structures of aspidostomides A–H (518–525) and aspidazide A (526) from the 
bryozoan Aspidostoma giganteum [184]. 
The Indian Ocean nudibranch, Aldisa andersoni, has afforded two phorbazoles, 9-chlorophorbazole D 
(527) and N1-methylphorbazole A (528) (Figure 101), in addition to the known phorbazoles A, B,  
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and D [185]. Both new phorbazoles show modest growth inhibition against the human cell lines A549, 
MCF-7, SKMEL-28 (melanoma), Hs683 (oligodendroglioma), and U373 (glioblastoma) in the range 
of IC50 18–29 µM and 19–34 µM for 527 and 528, respectively. These data are comparable or superior 
to the IC50 levels observed with carboplatin and temozolomide. 
 
Figure 101. Structures of phorbazoles 527 and 528 from the nudibranch Aldisa andersoni [185]. 
The Antarctic nudibranch Austrodoris kerguelenensis, collected near Palmer Station, produces 
sixteen new and some old diterpenoid glyceride esters, the palmadorins, several of which inhibit 
human erythroleukemia (HEL) cells. These are palmadorins A (529), B (530), D (531), M (532),  
N (533), and O (534) (Figure 102) [186]. One contains chlorine, the inactive palmadorin L (535) 
(Figure 102) [186]. The growth inhibition data for the active palmadorins are (IC50 µM): A (8.7),  
B (8.3), D (16.5), M (4.9), N (6.3), and O (13.4), respectively. 
 
Figure 102. Structures of palmadorins (529–535) from the nudibranch Austrodoris 
kerguelenensis [186]. 
Larger marine animals like gastropod molluscs are known to produce biologically active 
metabolites, some of which contain halogen. The anticancer properties of the lamellarins, which were 
first isolated from a marine mollusc, have been reviewed [187]. 
The Australian gastropod Dicathais orbita contains the well-known 6-bromoisatin which is active 
against the human cancer cell lines HT-29 and Caco2. It inhibits cell cycle progression of HT-29 cells 
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by arresting some cells in the G2/M phase, and induces apoptosis [188,189]. The Egyptian sea hare 
Aplysia oculifera has provided two new halogenated sesquiterpenes, oculiferane (536) and  
epi-obtusane (537) (Figure 103) [190]. Both compounds are cytotoxic (IC50 < 10 µg/mL) to the human 
cell lines PC-3 (prostate), A549, MCF-7, HepG2, and HCT 116, with these IC50 values (536/537): 
3.9/3.1, 3.1/0.96, 5.6/5.9, 3.3/2.4, and 5.9/4.1 µg/mL, respectively. 537 is comparable to 5-fluorouracil 
against A-549 (0.96 vs. 0.90 µg/mL). 
 
Figure 103. Structures of oculiferane (536) and epi-obtusane (537) from the sea hare 
Aplysia oculifera [190]. 
7. Antioxidants and Antiinflammation 
Because antioxidants can have anti-inflammatory activity, these two categories are combined. 
Like terrestrial phenolic compounds, marine phenols with antioxidant properties are well known, 
and several recent examples have appeared. The red alga Rhodomela confervoides from Liaoning 
Province, China, has afforded 19 bromophenols, six of which are new (538–543) (Figure 104) [191]. 
Two known examples, 544 and 545, are included because they are active in the radical scavenging 
assays. All 19 bromophenols were subjected to both the DPPH (1,1-diphenyl-2-picrylhydrazyl) and the 
ABTS (2,2′-azinobis(3-ethylbenzothiazoline-6-sulfonic acid)diammonium salt) free radical scavenging 
assays. Most of the bromophenols display more potent antioxidant activity than either BHT (butylated 
hydroxytoluene) or ascorbic acid. For the DPPH assay the most active compound is 539 (IC50 7.43 µM) 
followed by 544 > 543 > 545 > 538. In the ABTS assay 543 is the most active, followed by  
544 > 545 > 541. 
 
Figure 104. Structures of bromophenols 538–545 from the alga Rhodomela confervoides [191]. 
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Another study of Rhodomela confervoides has led to the discovery of five new nitrogen-containing 
bromophenols 546–550 (Figure 105) in addition to nine known analogues such as 551 [192]. In the 
DPPH assay bromophenol 546 shows the strongest activity (IC50 5.22 µM) (BHT, IC50 82.1 µM), 
followed by 548 > 547 > 551. In the ABTS assay, 551 is the most active, more active than ascorbic 
acid. The antioxidant capacity of these bromophenols seems to be correlated with the number of 
hydroxyl groups (or phenolic rings). 
 
Figure 105. Structures of bromocatechols 546–551 from the alga Rhodomela confervoides [192]. 
A specimen of the red alga Symphyocladia latiuscula from the coast of Qingdao, Shandong 
Province, China, has furnished the new bromocatechols 552 and 553 (Figure 106) [193]. Both are 
modest radical scavengers in the DPPH assay with IC50 14.5 and 20.5 µg/mL, respectively. Ascorbic 
acid shows IC50 7.82 µg/mL. The red alga Vertebrata lanosa, collected from Ullsfjorden, Norway, 
afforded the new bromocatechol 554 and the known 555–557 (Figure 106) [194]. Their antioxidant 
capacity was screened using these assays: ORAC (oxygen radical absorbance capacity), CAA (cellular 
antioxidant activity), and CLPAA (cellular lipid peroxidation antioxidant activity). This study is the first to 
measure the cellular antioxidant activity of bromocatechols. The antioxidant activity is highest for 555 
followed by 554, and then 556 and 557. At concentrations as low as 10 µg/mL, bromocatechol 555 
inhibits 68% of oxidation in the CAA assay. By comparison, the known antioxidants quercetin and 
luteolin at this same concentration (10 µg/mL) inhibit the oxidation of the CAA substrate  
(2′,7′-dichlorofluorescin) to the extent of 92% and 58%, respectively. 
Several marine sponges exhibit antioxidant behavior. The new 5,6-dibromo-L-hypaphorine (558) 
(Figure 107), along with four known bromoindoles, was isolated from the sponge Hyrtios sp. living in 
Fiji [195]. This new bromoindole displays significant antioxidant ability in the ORAC assay, only  
4-fold less active than Trolox (a water-soluble analogue of Vitamin E). A study of the antioxidant 
activity of the known Zyzzya fuliginosa sponge metabolites, zyzzyanones and makaluvamines reveals 
that the presence of a phenolic ring is essential for maximum activity in both the ABTS and APPH 
assays, and that a p-hydroxystyryl unit as in the makaluvamines (e.g., 559) is more important than a 
simple phenolic ring as in the zyzzyanones (e.g., 560) (Figure 107) [196]. 
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Figure 106. Structures of bromocatechols 552–556 from the red algae Symphyocladia 
latiuscula and Vertebrata lanosa [193,194]. 
 
Figure 107. Structures of 558–560 from the sponges Hyrtios sp. and Zyzza fuliginosa [195,196]. 
The novel iodinated acetylenic acid sponge metabolites 561–564, isolated from the South Korean 
Suberites mammilaris (561 and 562) and Suberites japonicus (563 and 564), were examined for their 
antiinflammatory activity (Figure 108) [197]. The methyl esters 561 and 562 strongly inhibit nitric 
oxide (NO) production from RAW 264.7 murine macrophase cells, with IC50 3.9 and 7.0 µM, 
respectively. However, in BV2 microglia cells, the methyl esters of 563 and 564 are the most active in 
NO inhibition: IC50 3.1 and 1.8 M, respectively. All four methyl esters attenuate the production of 
PGE2 (prostaglandin E2) from RAW 264.7 and BV2 cells as induced by LPS (lipopolysaccharide). 
The previously cited 4,5,6-tribromo-2,3-bis(methylthio)indole (121) (Figure 21) dramatically 
reduces the expression of both the pro-inflammatory enzyme i-NOS (inducible nitric oxide synthase) and 
COX-2 (cyclooxygenase) in LPS-activated RAW 264.7 cells. This indole has superior 
antiinflammatory activity relative to the other bromoindoles in this study [62]. Likewise, pitinoic acid 
B (199) (Figure 33) in LPS-stimulated differentiated THP-1 (human acute monocytic leukemia) cells 
decreases the level of the pro-inflammatory cytokines TNF-α (tumor necrosis factor alpha) and IL-6 
(interleukin 6), which probably accounts for the antiinflammatory effects of 200 [79]. Coibacin B (298) 
(Figure 53) also inhibits the gene transcription of the cytokines TNF-α, IL-6, IL-1b, and i-NOS. In the 
latter assay for NO production 298 has IC50 5 µM [114]. The didemnins from the tunicate 
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Trididemnum solidum (Figure 80) have pronounced antiinflammatory activity, particularly didemnin B 
(405), which inhibits i-NOS and NF-κB (nuclear factor-kappa B) expression, with IC50 0.002 and 0.03 µM, 
respectively. Chlorinated didemnin 402 shows IC50 0.4 and 0.26 µM, respectively [159]. Malyngamide 2 
(492) (Figure 94) has a value of IC50 8.0 µM in LPS-induced RAW 264.7 macrophages for the inhibition 
of NO production [175]. The herdmanines A–D (565–568) (Figure 109) from the Korean ascidian 
Herdmania momus inhibit the mRNA expression of i-NOS, and thereby suppress NO production with 
IC50 values of 90 and 9 µM, for 567 ad 568, respectively. These two herdmanines also inhibit PGE2 
production via the reduced mRNA expression of COX-2, and herdmanine D (568) inhibits the mRNA 
expression of IL-6 [198]. 
 
Figure 108. Structures of iodinated acetylenic acids 561–564 from the sponges Suberites 
mammilaris and S. japonicus [197]. 
 
Figure 109. Structures of herdmanines A–D (565–568) from the ascidian Herdmania momus [198]. 
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The Taiwanese gorgonian Junceella fragilis has afforded eight new 8-hydroxybriarane diterpenoids, 
frajunolides L–O (569–572) [199] and P–S (573–576) [200] (Figure 110). The antiinflammatory 
activities of these frajunolides were examined by measuring superoxide generation and elastase  
release by human neutrophils in response to fMLP/CB (formylmethionyl-leucyl-phenylalanine/ 
dihydrocytochalasin B. These data are summarized in Table 17. A similar set of briarane diterpenoids 
was characterized in the gorgonian Junceella juncea, juncenolides M–O (577–579) (Figure 111) [201]. 
The antiinflammatory activity of these juncenolides is shown in Table 17. Of the frajunolides L–S, P 
and Q are the most active on both superoxide anion generation and elastase release. Of the 
juncenolides M–O, O is the most active and N shows inhibition against elastase release. The gorgonian 
Briareum sp. collected in Taiwan yielded the novel dichlorinated briarenolide J (580) (Figure 111), 
which also displays antiinflammatory activity (Table 17) [202]. It would appear that frajunolide S 
(576) is identical with juncenolide M (577). 
 
Figure 110. Structures of frajunolides L–S (569–576) from the gorgonian Junceella  
fragilis [199,200]. 
 
Figure 111. Structures of juncenolides M–O (577–579) from the gorgonian Junceella juncea [201]. 
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Table 17. Effect of frajunolides L–S (569–576), juncenolides M–O (577–579), and 
briarenolide J (580) on superoxide anion generation and elastase release in response to 
fMLP/CB. 
 % Inhibition a 
Compound Superoxide Anion Elastase Release 
frajunolide L (569) 18.7 16.2 
frajunolide M (570) 2.0 13.3 
frajunolide N (571) 0.6 22.3 
frajunolide O (572) 8.3 17.2 
frajunolide P (573) 32.5 35.6 
frajunolide Q (574) 28.7 34.1 
frajunolide R (575) 9.7 16.0 
frajunolide S (576) 5.8 −4.5 
juncenolide M (577) 7.6 15.9 
juncenolide N (578) 6.7 29.0 
juncenolide O (579) 27.6 35.9 
briarenolide J (580) 14.98 9.96 
genistein 65.0 51.6 
a % inhibition at 10 µg/mL concentration. 
Marine bacteria have yielded some antiinflammatory compounds, such as Streptomyces sp. CNS284 
which produces 2-bromo-1-hydroxyphenazine (581) (Figure 112), which has some activity in the  
NF-κB-luciferase assay (IC50 73 µM) [203]. Several synthetic analogues are more active than 581 and 
show potent inhibition of i-NOS expression and display chemoprevention, QR1 (quinone reductase 1) 
induction and QR2 (quinone reductase 2) inhibition. The two novel phenazines, 582 and 583, were 
characterized from the same Streptomyces sp. CNS284 along with the known lavanducyanin (584) 
(Figure 112) [204]. All three phenazines inhibit TNF-α-induced NF-κB activity (IC50 4.1, 24.2, and  
16.3 μM, respectively), and LPS-induced NO production (IC50 > 48.6, 15.1, and 8.0 µM, respectively). 
The blocking of PGE2 production was even more efficient (IC50 7.5, 0.89, and 0.63 µM, respectively). 
This study also shows that lavanducyanin inhibits the activity of COX-1 and COX-2, in addition to the 
production of NO and PGE2. 
 
Figure 112. Structures of phenazines (581–584) from Streptomyces sp. CNS284 [203,204]. 
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8. Enzymatic and Molecular Activity 
Overshadowed by the biological effects presented in the previous sections are molecular 
interactions between the marine natural products and the target molecules (enzymes, peptides, and 
other small biological molecules) that are the root cause of these effects. A review of the targeting of 
marine natural products to cytoskeletal proteins has appeared [205]. 
Several marine brominated natural products are protein kinase inhibitors. Purpuroines A (59) and  
D (62) (Figure 11) are selective inhibitors of the kinase LCK (lymphocyte-specific protein tyrosine 
kinase) with IC50 2.35 and 0.94 µg/mL, respectively. Purpuroine D is inhibitory towards PLK1 
(serine/threonine-protein kinase) with IC50 0.94 µg/mL. For comparison, staurosporine shows IC50 
3.73 and 0.92 µg/mL for LCK and PLK1, respectively. All of the purpuroines are weak inhibitors to 
CDK2 (cyclin-dependent kinase 2) (IC50 > 50 µg/mL) [46]. The study of the massadines (Figure 12)  
re-established that the known debromohymenialdisine and hymenialdisine are nanomolar kinase 
inhibitors of CDK5/P25 (cyclin-dependent kinase 5), CD1δ (casein kinase 1), and GSK3β (glycogen 
synthase kinase 3β): IC50 0.4, 0.1, and 0.2 µM, respectively, for debromohymenialdisine, and IC50 
0.16, 0.03, and 0.07 µM, respectively, for hymenialdisine [47]. The novel sesquibastadin 1 (367) and 
bastadin 3 (Figure 71) are strong inhibitors of at least 22 protein kinases (IC50 0.1–6.5 µM).  
For example sesquibastadin 1 causes potent inhibition of the receptor tyrosine kinases EGF-R and 
VEGF-R2 (both IC50 0.6 µM), and of T1E2 (IC50 0.6 µM). Bastadin 3 is a potent inhibitor of Aurora A 
and B (IC50 0.1 and 0.5 µM, respectively). This bastadin inhibits all of the examined kinases at 
submicromolar activity. The other bastadins 6, 7, 11, and 16 are either inactive or much less active, 
exactly the opposite to their cell proliferation inhibitory activity (vide supra) [139]. A study of the 
known ageladine A, and synthetic analogues, against a battery of kinases shows that ageladine A has 
modest activity towards the tyrosine kinase DYRK1A and Pim 1 [206]. The Indonesian sponges 
Stylissa massa and Stylissa flabelliformis yielded 25 bromopyrroles, including the new dispacamide E 
(585) and 586 (Figure 113) [207]. All isolated compounds were assayed against these protein kinases: 
DYRK1A, CDK5, GSK-3, CLK-1, CK-1, CDK1, CDK2/A, CDK9/cyclin T, and Plasmodium 
falciparum glycogen synthase kinase-3 (PfGSK-3). Dispacamide E is particularly active against GSK-3, 
DYRK1A and CK-1 (IC50 2.1, 6.2, and 4.9 µM, respectively). The known hymenine and some 
hymenialdisine derivatives are very active against PfGSK-3 with IC50 in the nanomolar range [207]. 
The red alga Laurencia similis from the Hainan coast, China, has afforded five new polybrominated 
compounds, 587–591 (Figure 114) [208]. The brominated N-bromo-2-naphthylamines 588–590 are 
remarkably unique structures, unlike the brominated diphenyl ether 587 and benzophenone 591, for 
which many examples are known. Metabolites 587 and 591 are inhibitory towards PTP1B (protein 
tyrosine phosphatase B) with IC50 2.97 and 2.66 µM, respectively. The Yesinia outer protein (YopE), 
which is also a protein tyrosine phosphatase, is inhibited by pseudoceramines B (52) and D (54) 
(Figure 9), with IC50 19 and 6 µM, respectively [44]. This enzyme is essential for bacterial virulence of 
the Gram-negative Yersinia spp. 
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Figure 113. Structures of dispacamide E (585) and pyrrole 586 from the sponges Stylissa 
massa and Stylissa flabelliformis [207]. 
 
Figure 114. Structures of polybromides 587–591 from the red alga Laurencia similis [208]. 
The known helicusin A which was isolated from the fungus Bartalina robillardoides strain LF550 
along with three new chloroazaphilones (Figure 27), shows inhibition of acetylcholinesterase (IC50 2.1 µM) 
(the positive control hyperzine has IC50 < 0.1 µM). In this study the known deacetylsclerotiorin 
inhibits phosphodiesterase 4 (IC50 2.79 µM), as does isochromophilone XI (164), albeit weaker (IC50 
8.30 µM). (The positive control rolipam has 0.75 µM) [71]. The new pulmonarins A (592) and B (593) 
(Figure 115), isolated from the clonial ascidian Synoicum pulmonaria living on the coast of Tromsø, 
Norway, are reversible, noncompetitive inhibitors of acetylcholinesterase; Ki = 90 µM and 20 µM, 
respectively. Relative to 593, the Calabar bean alkaloid physostigmine has Ki = 30 nM [209]. The 
South China Sea sponge Xestospongia testudinaria has yielded the novel mutafuran (594) (Figure 115) 
along with three known bromine-containing polyacetylenes [210]. Mutafuran shows significant 
acetylcholinesterase activity (IC50 0.64 µM). The positive control tacrine, which is used to treat early 
stage Alzheimer’s disease, has IC50 0.41 µM. 
 
Figure 115. Structures of pulmonarins A (592) and B (593) from the ascidian Synoicum 
pulmonaria [209] and mutafuran H (594) from the sponge Xestospongia testudinaria [210]. 
Several marine organohalogens discovered in the timeframe of this survey are protease inhibitors. 
The Ianthella sp. sponge metabolites dictyodendrin F, H, I, and J (Figure 14) are potent inhibitors of 
BACE 1 (β-secretase 1) with IC50 values of 1.0–2.0 µM). Only dictyodendrin G (75) is inactive [49]. 
The known cyanobacterium fischerindole hapalosin inhibits the 20s proteasome (IC50 12 µM), whereas 
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the other fischerindoles isolated in this study (Figure 92) are inactive [173]. Extensive studies of the 
cyanobacteria Microcystis aeruginosa and Microcystis spp. in Israel and India have revealed several 
novel aeruginosins. These are aeruginosin GE686 (595), GE766 (596), GE730 (597), GE810 (598), 
GE642 (599) [211], IN608 (600), IN652 (601) [212], LH650A (602), LH650B (603), LH606 (604), 
and the nonchlorinated microviridin LH1667 [213] (Figure 116). Several known analogues were also 
isolated from these blooms. The aeruginosins are inhibitors of the serine proteolytic enzymes trypsin and 
thrombin. The trypsin inhibitory activities (IC50 µM) are best realized for GE686 (595), 3.2; GE730 
(597), 2.3; IN608 (600), 4.3; IN652 (601), 4.1; and LH606 (604), 18.5. The thrombin inhibitory 
activities (IC50 µM) are best seen for GE686 (595), 12.8; GE730 (597), 12.9; LH650A (602), 1.8; 
LH650B (603), 1.8; and LH606 (604) 2.5. Microviridin inhibits chymotrypsin, IC50 2.8 µM [211–213]. 
 
Figure 116. Structures of aeruginosins 595–604 from the cyanobacteria Microcystis 
aeruginosa and Microcystis spp. [211–213]. 
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Figure 117. Structures of bromotyrosines 605–611 from the sponges Aplysinella sp. and 
Callyspongia sp. [214,215]. 
Some marine sponge metabolites increase the production of ApoE (apoliproprotein E), an important 
enzyme that mediates cholesterol metabolism, which has implication in the treatment of Alzheimer’s 
disease. The Great Barrier Reef, Australia, sponge Aplysinella sp. has afforded three new aplysinellamides 
A–D (605–607) and aplysamine-1-N-oxide (608) (Figure 117) along with six known analogues. 
Amongst the latter, aplysamine-1 displays ApoE-modulating activity by increasing by 2-fold the 
secretion of ApoE from human astrocytoma cells at a concentration of 30 µM [214]. Likewise, the 
Australian sponge Callyspongia sp. has yielded the new bromotyrosines 609–611, along with ten known 
compounds (Figure 117). Of these, 610 shows weak ability to increase ApoE from human astrocytoma 
cells (CCF-STTG1) at a concentration of 40 µM [215]. 
The sponge Xestospongia testudinaria has yielded five new brominated fatty acids, 612–616  
(Figure 118), which include testufuran A (612), similar to mutafuran H (594) (Figure 115) isolated 
from the same sponge. An additional 11 known brominated acetylenic acids were also characterized. 
Most of these 16 bromo carboxylic acids stimulated the secretion of the protein hormone adiponectin, 
which regulates glucose levels and fatty acid breakdown, from differentiated ST-13 preadipocytes. 
These compounds do not exhibit agonistic activity against PPAR-γ (the peroxisome proliferator-activated 
receptor) [216]. 
The ascidian Herdmania momus has yielded seven new herdmanines E–K (617–623) (Figure 119), 
some of which demonstrate significant PPAR-γ activation in Ac2F rat liver cells. The active examples 
are I (621) and K (623). For example, the latter herdmanine K exhibits strong PPAR-γ activation  
at 1 and 10 µg/mL concentrations, with greater potency than the antidiabetic drug rosiglitazone.  
The known (–)-leptoclinidamine B was also isolated from the ascidian and is only slightly less active 
than 623 [217]. 
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Figure 118. Structures of bromo carboxylic acids 612–616 from the sponge Xestospongia 
testudinaria [216]. 
 
Figure 119. Structures of herdmanines E–K (617–623) from the ascidian Herdmania momus [217]. 
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Figure 120. Structures of placotylenes A (624) and B (625) from the sponge  
Placospongia sp. [218] and chalinulasterol (626) from the sponge Chalinula molitba [219]. 
The two rare iodinated polyacetylenes, placotylenes A (624) and B (625), were characterized in the 
Korean sponge Placospongia sp. (Figure 120). Placotylene A inhibits osteoclast differentiation of bone 
marrow-derived macrophages, perhaps by decreasing the expression of RANKL (receptor activator of 
nuclear factor-κB ligand). This marine polyacetylene could represent a lead compound for osteoporosis 
treatment [218]. The Caribbean sponge Chalinula molitba has afforded the novel chlorinated sterol 
disulfate, chalinulasterol (626) (Figure 120). Despite the resemblance of chalinulasterol to the known 
PXR (pregnane X receptor) agonist solomonsterol A (627), no activity is observed for the former 
sterol. This important receptor regulates expression of drug metabolizing and detoxifying enzymes [219]. 
Two sets of metabolites from the ascidian Synoicum sp. exhibit inhibition of the peptidase-type 
proteins sortase A and isocitrate lyase, two enzymes that have important functions in the virulence and 
survival of pathogenic bacteria. Thus, of the eudistomins cited earlier (Figure 23), Y4 (134) and Y5 
(135) show modest activity toward sortase A (SrtA) (IC50 163.2 and 146.4 µM, respectively), whereas 
Y2 (132) shows IC50 50.2 µM against isocitrate lyase (ICL) [65]. Of the brominated aromatic 
furanones examined (Figure 24), cardiolide E (138) inhibits SrtA (IC50 78.8 µM), and cardiolides E 
(138) and I (142) show IC50 8.9 and 10.8 µM, respectively, for SrtA [67]. These Synoicum metabolites 
also inhibit the enzyme Na+/K+-ATPase (sodium-potassium adenosine triphosphatase) as follows: Y4 
(134), Y6 (136), Y7 (137), cardiolide E (138), and cardiolide I (142) give these values: 7.5, 10.1, 11.3, 
2.5, and 5.0 µM, respectively [65,67]. This enzyme is a sodium-potassium pump with several functions. 
A combined Curacao and Papua New Guinea collection of cyanobacteria has yielded five new 
vinylchloride metabolites, janthielamide A (628), kimbeamides A–C (629–631), and kimbelactone A 
(632) (Figure 121). Janthielamide A came from the collection at Jan Thiel Bay in Curacao, and the 
latter four metabolites came from the collection at Kimbe Bay, New Britain, Papua New Guinea. 
Janthielamide A (628) exhibits Na+ channel blocking in murine Neuro-2a cells (IC50 11.5 µM), and 
also antagonizes induced Na+ influx in neurons (IC50 5.2 µM). Kimbeamide A (629) displays similar 
Na+ blocking activity at a concentration of 20 µg/mL, but it, along with the 630–632, undergoes oxidative 
decomposition [220]. 
The new isomalbrancheamide B (633), along with three known analogues, was isolated from the 
fungus Malbranchea aurantiaca (Figure 122). Isomalbrancheamide B (633) and the known 
malbrancheamide (634) and malbrancheamide B (635) are classical CaM (calmodulin) inhibitors, 
whereas the nonchlorinated premalbrancheamide (636) is not. Malbrancheamide (634) is the most 
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active, and it binds to the same hydrophobic pocket as the antipsychotics chlorpromazine and 
trifluoperazine, two classical CaM inhibitors [221]. 
 
Figure 121. Structures of janthielamide A (628), kimbeamides A–C (629–631), and 
kimbelactone A (632) from cyanobacteria [220]. 
 
Figure 122. Structures of malbrancheamides 633–636 from the fungus Malbranchea 
aurantiaca [221]. 
The previously cited 5,6-dibromo-L-hypaphorine (558) (Figure 107) from the sponge Hyrtios sp. is 
a weak inhibitor of bee venom phospholipase A2 (PLA2). Relative to the positive control, manoalide 
(IC50 0.5 µM), 558 has IC50 0.20 mM [195]. The red alga Laurencia okamurai has yielded the new 
chamigrane, okamurene E (637), and the new C12-acetogenin, okamuragenin (638) (Figure 123), along 
with the known okamurenes A–D and nine known sesquiterpenes and four known C15-acetogenins. All 
of these compounds were evaluated for toxicity against brine shrimp (Artemia salina). Of all 
compounds, only 7-hydroxylaurene (639) expressed lethal toxicity with LD50 1.8 µM [222]. 
 
Figure 123. Structures of okamurene E (637) and okamuragenin (638) from the red alga 
Laurencia okamurai, and 7-hydroxylaurene (639) [222]. 
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The marine-derived fungus Aspergillus sp. SCSGAF0093 produces nine mycotoxins, four of which 
are new, aluminiumneoaspergillin (640), zirconiumneoaspergillin (641), aspergilliamide (642), and 
ochratoxin A n-butyl ester (643) (Figure 124). This is the first report of marine-based ochratoxins 
(ochratoxin and the methyl ester were also isolated), and the first discovery of a zirconium complex 
(641) in nature [223]. All nine compounds exhibit some toxicity to brine shrimp. The most toxic 
compounds in this assay are 643, ochratoxin A, and ochratoxin A methyl ester, with IC50 4.14, 13.74, 
and 2.59 µM, respectively. 
 
Figure 124. Structures of mycotoxins 640–643 from the fungus Aspergillus sp. 
SCSGAF0093 [223]. 
The innocent-looking, but ominous cone snails (genus Conus) comprise about 700 species  
and are widely distributed in the world’s oceans [224]. It is estimated that these cone snails contain 
more than 50,000 distinct toxins, since the venom in each Conus species consists of 40–200 individual 
peptides with a unique biological action [225–227]. Many of these Conus sp. peptides contain  
6-bromotryptophan [3], the function of which has been suggested to block proteolytic degradation 
since the large bromine makes the peptide a poor fit for docking in the active site of chymotrypsin [228]. 
Recent studies have established the binding site of α-conotoxin Vc1.1 from Conus victoria on the 
nicotinic α9α10 acetylcholine receptor, making this toxin a potential novel treatment for neuropathic 
pain [229]. A similar α-4/6-conotoxin TxID has been identified in Conus textile. It also blocks nicotinic 
acetylcholine receptors [230]. The conopeptide MVIIA (Ziconotide; Prialt) was approved by the U.S. 
FDA in 2004 for the treatment of severe pain.  
9. Conclusions 
Marine organisms possess an astonishing array of biological activities! The chemical compounds 
they produce proffer future medicinal developments in a multitude of human diseases. Of these 
compounds, organohalogen natural products frequently display the highest level of biological activity. 
The unceasing developments in aquatic exploration, organism collection, compound isolation and 
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identification, and biological assays guarantee that new marine natural products are awaiting discovery, 
biological evaluation, and possible benefit to mankind.  
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